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ABSTRACT 
UPREGULATION OF ANGIOGENIC FACTORS BY PITUITARY TUMOR 
TRANSFORMING GENE (PTTG) IN TUMORIGENESIS 
MOHAMMAD TARIQ MALIK 
May, 25TH 2006 
Pituitary tumor transforming gene (PTTG), also known as seCUrIng, is a novel 
oncogene that is expressed at high levels in most of the tumors analyzed to date. 
Overexpression of PTTG in mouse fibroblast (NIH 3T3) cells increases cell 
proliferation, induces cellular transformation and promotes tumor formation in nude 
mice. PTTG is a multi-domain and multifunction protein. Some functions of PTTG 
include inhibition of pre-mature sister chromatid separation, activation of transcription 
of c-myc oncogene, cell cycle regulation, and DNA repair. In some cancers such as 
thyroid, pituitary, esophageal, and colorectal tumors, high PTTG expression correlates 
with metastasis and poor prognosis. The PTTG gene encodes a protein of 203 amino 
acids and is consists of six exons and four introns. The PTTG promoter is specifically 
activated in tumors and is highly regulated by Sp 1 and NF -Y nuclear factors. 
However, the precise mechanism by which PTTG mediates its tumorigenic function 
remains unclear. To this end, we determined the effect of PTTG on tumor metastasis 
and angiogenesis by determining its effect on secretion and expression of various 
VI 
angiogenic and metastatic factors including bFGF, VEGF, IL-8 and MMP-2. Using 
R T IPCR, ELISA and zymography we showed a significant increase in expression and 
secretion ofbFGF, VEGF, IL-8 and MMP-2 in HEK293 cells on transfection ofPTTG 
eDNA. Down regulation of PTTG expression by siRNA and a genetically deleted 
HCT116 (PTTG -1-) cell line showed significantly decrease in expression of MMP-2, 
which led to decreased invasion and migration of HCT116 (PTTG-I-) cells as 
compared to the HCTl16 wild type. Taken together, our results confirm that PTTG is 
a potent tumorigenic gene that exerts its tumorigenic functions by increasing secretion 
and expression of VEGF, bFGF, IL-8 and MMP-2 and MTI-MMP. In addition 
expression of other angiogenic and adhesion molecules including beta-I, beta-3, 
alpha-5 and alpha-V integrins was also modulated by PTTG in HEK293 cells. 
Vll 
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Cancer is the second leading cause of death in the United States. An estimated 
1.4 million new cases and 570 thousand deaths are expected in the year 2006 (1). 
Overall worldwide, every year more than 11 million people are diagnosed with cancer, 
leading to an estimated seven million deaths (2). Despite substantial advances made in 
understanding tumorigenesis, complete knowledge of the underlying mechanisms that 
lead to cancer initiation and progression remain unclear. Some of the factors that have 
been reported to influence cancer development include, but are not limited to 
environmental factors, genetic predisposition, and aging. Cancer development is a 
complex and multi-step process that involves activation of proto-oncogenes, growth 
factors, and their receptors, or deregulation of tumor suppressor genes leading to 
abnormal cellular processes. Most importantly, the cancer cells exploit every 
opportunity to deviate from the standard functions and restraints of normal cells. 
Genetic aspect of cancer can be traced back more than 100 years when von-
Hansenmann in 1890 and Boveri et al. in 1914 suggested aneuploidy, due to 
chromosomal missegregation, as the fundamental basis of cancer (3-5). Since the 
Boveri prediction it now seems that all solid tumor cells are not only aneuploid (6) but 
they have acquired a number of mutations in oncogenes and tumor suppressor 
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genes. Some of these genes include KRAS, TP53, APC, BRCAl, and RBI among 
others. In addition cancer cell lines show a high level of chromosomal instability 
(CIN) as a result of the loss or gain of whole chromosome or partial loss of 
chromosomes during cell division (7). 
The cause of chromosomal instability (CIN) is unknown, but one idea is 
that it occurs due to a defect in the processes that control chromtid separation 
during mitosis (8). Whether aneuploidy is a contributor, or just a reason for tumor 
development, remains unanswered. It is known that a tumor originates from a 
single altered cell, followed by sequential somatic, genetic or epigenetic changes 
over a generation with increased aggressive subpopulation within the tumor mass 
(9,10). Somatic evolution phenomena have been confirmed by numerous 
molecular studies; it has been estimated that cells have to acquire five to seven 
successive mutations to allow tumor growth, invasion and metastasis (11-13). 
To identify the cause of tumorigenesis many cancer-causing genes have 
been identified. Although they differ from tumor to tumor, loss or change in their 
functions allows most cancers to acquire phenotypic differences. Hanahan and 
Weinberg (14) described in detail phenotypic differences between healthy and 
cancerous cells. The basic six phenotypic changes reported to occur at the cellular 
level as essential hallmarks of cancer are: (a) unlimited mitosis; (b) evasion of 
apoptosis; (c) resistance to growth-inhibition signals; (d) tissue invasion and 
metastasis; (e) sustained angiogenesis; and (f) escape from the dependence on 
external growth stimulation (14). Genetic instability is an additional factor which 
accounts for the high incidence of mutations in cancer cells. Cancer susceptible 
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genes can be generally categorized into three classes: gatekeepers, caretakers and 
landscapers (15,16). 
Broadly speaking, gatekeeper genes are divided into two categories: (1) 
oncogenes and (2) tumor suppressor genes (17,18). Mutations in any or both of 
these types of genes operate similarly at the physiological level, and can exert 
positive or negative regulatory properties on cell growth and proliferation. 
Oncogenes are frequently activated by gain-of-function mutations, fusion with 
other genes, amplification, increased expression as a result of increased promoter 
activity, or protein stabilization (19,20). Hence these oncogenes genes play an 
important role in diverse signaling pathways involved in various stages of human 
cancer initiation, progression, angiogenesis and metastasis (17). Caretakers, or 
stability genes, function to maintain the genomic integrity of the cell and regulate 
DNA repair mechanisms, chromosome segregation and cell cycle check points 
(18). Defects in caretaker genes lead to genetic instabilities that contribute to the 
mutations in other genes, including oncogenes and suppressor genes that directly 
affect cell proliferation and survival, thus promoting tumorigenesis (21-23). 
Defects in landscaper genes do not directly affect cellular growth, but instead 
generate an abnormal stromal environment that contributes to neoplastic 
transformation of cells (17,23). Some examples of landscaper genes are 
metalloproteinases (MMPs), uroplasminogen activator (uP A), tissue plasminogen 
activator (tPA), fibroblast growth factor-2 (FGF-2) , and platelet-derived growth 
factor (PDGF). 
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In summary, cancer is a complex and multistep genetic disease that 
involves accumulation of genetic changes in somatic cells. These genetic changes 
often involve activation of oncogenes and inactivation or loss of tumor suppressor 
genes. However the mechanisms that initiate and promote tumorigenesis remain 
unclear. 
1.1 PITUITARY TUMOR TRANSFORMING GENE (PTTG) 
To help understand the mechanisms of human tumorigenesis and to 
identify the possibility for the existence of a common gene or signaling 
mechanism, our laboratory cloned and characterized a novel oncogene: the 
pituitary tumor transforming gene (PTTG), also known as mammalian securin, 
from human testis (24) and ovarian tumors (25). Our initial studies were based on 
the work of Pei et al (26), who used an mRNA differential display technique to 
clone PTTG from a rat pituitary tumor. We and others showed that induction of 
PTTG in mouse NIH3T3 fibroblast cells induces cell transformation in vitro and 
in vivo (26-28). PTTG was found to be expressed in almost all tumors analyzed to 
date, including tumors derived from the pituitary, adrenal, thyroid, liver, kidney, 
endometrium, uterus, breast, testis, ovary, colon, as well as melanoma, leukemia 
and various cell lines derived from these tumors (24,26,29-35). Expression of 
PTTG is either very low or undetectable in normal tissues, except in the testis. 
PTTG is reported to be a novel oncogene shown as a molecular signature gene, 
whose expression in solids tumors is associated with metastasis and poor 
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prognosis (36). Inactivation ofPTTG results in chromosomal loss with high levels 
of chromosomal instability (37,38) and a defect in cell division (39). 
Overexpression of PTTG causes tumor formation in nude mice (26) and tumor 
cells are aneuploid (40,41). A strong correlation between aneuploidy, genomic 
instability and overexpression of PTTG was shown by Kim et al (42) in follicular 
thyroid cancer cells. Zhang et al (35) showed a positive correlation between 
PTTG levels and invasiveness of pituitary tumors. Similarly, Genkai et al (43) 
showed a higher level of expression of PTTG in high grade tumor tissues from 
patients with poor prognosis. PTTG has also been shown to be involved in 
angiogenesis by inducing the expression and secretion of PGP (27) and VEGP 
(44). In summary, PTTG is an important proto-oncogene, involved in many 
cellular processes, and importantly, in tumorigenesis. Therefore, understanding 
the mechanism by which PTTG induces tumorigenesis will help in identifYing 
new signaling pathways and gene products that may help to understand complex 
diseases and allow for the development of novel and more potent therapeutics 
opportunities. 
1.2 PRIMARY STRUCTURE OF PTTG 
PTTG cDNA cloned from testis (24) and ovarian tumors (25) is composed 
of 656 nucleotides, and encodes a protein of 202 amino acids, with an 
approximate molecular weight of 24 kDa (25). However, PTTG migrates at 28 -
30 kDa on SDS-PAGE\ suggesting post-translational modifications (27,34,45,46). 
5 
PTTG also migrates as a doublet, which is suggestive of phosphorylation status as 
shown in (i (26,47). 
Sequence analysis of the PTTG protein showed no homology to other 
proteins in the human genome (24,26). It is a multi-domain, natively unfolded 
protein (48), and can be divided into two parts: the N-terminal regulatory domain 
and C-terminal functional domain. The N-terminus contains a KEN box and D-
box surrounded by lysine residue, and serves as a target for anaphase promoting 
complex (APC) for degradation (Figure 2) (49). A mutation in the KEN box does 
not prevent PTTG degradation, while a mutation in the D-box region partially 
prevents degradation (45). However, a mutation in both KEN and D-boxes 
completely abolishes PTTG degradation (50). The C-terminal functional domain 
is more acidic and contains proline-rich motifs (PXXP), a casein kinase II (CKII) 
phosphorylation site, and cyclic AMP and cyclic GMP protein kinase 
phosphorylation sites (27,29,30,47). The proline-rich domain (PXXP) is known to 
bind to various Src homology 3 (SH3) domain-containing proteins (51-53). The 
SH3 binding domains mediate protein-protein interactions in signal transduction, 
suggesting that PTTG may interact with other proteins that control its function, 
regulation or trans-localization. However, no protein that interacts with these 
sites has been identified. 
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Figure 1: PTTG is expressed in cell cycle dependent manner. A doublet for 
phosphorylated PTTG protein is observed at M phase of cell cycle suggesting 
potential for PTTG phosphorylation. 
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Figure 1 
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Figure 2: Major functional domains of PTTG, including DNA binding domain, 
transactivation domain, and the critical proline rich (SH3) domains. Taken from 
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However, the PXXP domains of PTTG have been reported to be involved in 
bFGF and VEGF transactivation (55), as well as being involved in cell 
transformation (27). It has been reported that serine 165 within the proline-rich 
domain is the sole phosphorylation site for cyclin dependent kinase-2 (cdc2), (47) 
and MAPK (56) is necessary during cell division to facilitate the function of 
PTTG (47,55). Deletion or mutation of the proline-rich motifs abolishes the 
transformation and tumorigenesis function of PTTG (27,55). Mutation of the 
analogous murine serine at 162 position reduces PTTG mediated transactivation 
by 75% (57). PTTG is mainly present in the cytoplasm with a partial nuclear 
localization. Although PTTG lacks a nucloor localization sequence, the protein is 
directed to the nucleus by interaction with PTTG binding factor (PBF) (47,56) or 
phosphorylation by mitogen-activated protein kinase (MAPK) (56). It has also 
been speculated that the small size of PTTG may help in the translocation into the 
nucleus. In addition, PTTG has been shown to interact with p53 (58), Ku-
heterodimer (59), ribosomal protein S10, and a novel human homologue of 
bacterial heat shock protein DnaJ; HSJ2 (60). 
1.3 PTTG FAMILY OF GENES 
The PTTG genes cloned from three species (rat, mouse and human) are 
highly homologous. The human homologue of PTTG shares approximately ~80 
% homology at the amino acid and nucleotide level, respectively, with the rat and 
mouse genes. The PTTG gene was mapped to human chromosome 5q35.l, a 
locus frequently associated with the reoccurrence of lung cancer and leukemia 
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(Figure 3) (61,62). In adult human tissues, PTTG is most abundantly expressed in 
testis, as well as in thymus, colon, small intestine, brain, placenta and pancreas 
(24). Two additional members of the PTTG family have been identified (30). 
After cloning of these members, PTTG was renamed as PTTG 1 and the other two 
members as PTTG2 and PTTG3. All members of the family are transcribed from 
different genes located on different chromosomes. PTTG 1 mapped to 
chromosome 5q35.1 (61), PTTG2 to chromosome 4p12, and PTTG3 to 
chromosome 8q22. PTTG 1 and PTTG3 encode the proteins of 202 amino acids. 
Structurally they are same, but the function PTTG3 is not known (30,63). PTTG2 
contains a deletion at nucleotide 541 which results in a frame shift and an early 
stop codon, resulting in a truncated protein of 191 amino acids (Figure 4). 
PTTGl, PTTG2 and PTTG3 are differentially expressed in normal and tumor 
tissues (30). PTTG 1 has been most extensively studied. For simplicity, we will 
refer to PTTG 1 as PTTG for the remainder of this dissertation. 
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Figure 3: Genomic organization of the human PTTG. PTTG gene is located on 
Chromosome 5 at 5q35.1. PTTG has six eKon and five introns and spans at least 
10 kb. The cDNA is composed of 656 nucleotides and encodes a protein of 202 
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Figure 4: Amino acid sequence alignment of PTTG!, PTTG2 and PTTG3 gene 



















1.4 BIOLOGICAL ROLES OF PTTG IN NORMAL CELLULAR 
FUNCTIONS. 
PTTG is a multi-functional protein that plays critical roles in cell cycle 
progression, chromosomal stability and cell division (64,65). PTTG functions as 
human securin to ensure that there is no premature separation of sister chromatids 
by inhibiting separase, which is liberated from securin to degrade cohesin bound 
to sister chromatids at anaphase (Figure 5) The level of PTTG expression is 
increased rapidly in proliferating cells and is regulated in a cell cycle-dependent 
manner (47,66). PTTG mRNA and protein-levels are low at the GIIS inter-phase, 
and gradually increases during S phase with maximum expression at M phase. 
PTTG undergoes complete degradation at anaphase by ubiquitinization and by the 
recognization of the destruction box (D-box) consensus sequence of RxxLxxxxN 
(67). The daughter cells after cell division express low levels of PTTG protein 
(45). Overexpression of PTTG inhibits separation of sister chromatids, resulting 
in gene translocations, truncations and unequal number of chromosomes in 
daughter cells (aneuploidy) (41,66). 
1.5 EXPRESSION AND BIOLOGICAL ROLE OF PTTG IN 
TUMORIGENESIS. 
PTTG is abundantly expressed only in testis where it is believed to be 
necessary for normal spermatogenesis (24). Moderate expression is found in the 
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Figure 5: PTTG expression is cell cycle dependent. The mRNA and protein 
expression of PTTG are low at the G 1 / S interphase, gradually increases during S 
phase and peaking at G2 / M phase. PTTG is degraded as the cells enter the 














thymus, colon, and small intestine, brain, and pancreas (27), and very low or 
undetectable levels are found in the kidney, ovary, breast, liver and adrenal 
(49,60). In contrast, high levels ofPTTG mRNA and protein are detected in most 
tumors including tumors of the pituitary, adrenal, ovary, endometrium, liver, 
colon, lung, stomach, breast, thyroid and testicles (24,25,33,35,68-70). In colon 
cancers, expression of PTTG strongly correlates with the degree of angiogenesis 
and metastasis (33). The pituitary tumor transforming gene (PTTG) has been 
shown as a signature gene among eight other genes associated with highly 
metastatic solid tumors, and its expression was associated with metastasis and 
poor prognosis (36). A relationship between the survival rate and level of 
expression of PTTG in esophageal cancer has also been reported (71). 
Overexpression of human PTTG in mouse NIH3T3 fibroblasts and human 
embryonic kidney (HEK293) cells resulted in increased cell proliferation, 
induction of cells to form foci in monolayer culture and promotion of tumor 
formation in nude mice (24,26,27,72). These results clearly suggest that PTTG is 
a human oncogene. 
The most important candidates for downstream targets of PTTG function 
are c-myc oncogene and basic fibroblast growth factor (bFGF). Induction of 
PTTG results in increased cell proliferation through activation of c-myc (73), 
suggesting direct transactivation of c-myc by PTTG. In recent studies, Bernal et 
al. (58) reported interaction of the PTTG protein with the p53 protein thereby 
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blocking the specific binding of p53 to DNA resulting III inhibition of its 
transcriptional activity (Figure 6). 
As mentioned earlier, PTTG possesses transactivation activity (29,56). 
Transient transfection of a fusion construct containing the GAL4-DNA-binding 
domain linked to the C-terminal region of PTTG which contains the multiple 
glutamic acid and proline residues characteristic of transcription activation 
domains trans activates a luciferase reporter gene (29). PTTG mutants defective in 
transactivating activity are unable to transform mouse fibroblast NIH3T3 cells, 
suggesting that transactivating activity is im.portant for the oncogenic functions of 
PTTG. Importantly, PTTG interacts with the c-myc oncogene product. Induction 
of PTTG results in increased cell proliferation through the activation of c-myc 
(73) by binding to the c-myc promoter near the transcriptional initiation site. 
Furthermore, inactivation of PTTG results in chromosomal loss with high levels 
of chromosomal instability (37,38). PTTG knockout mice show high levels of 
chromosomal instability and abnormal cell division (39). On the other hand, over-
expression of PTTG promotes tumors in nude mice (26), and these tumors are 
aneuploid (40,41). Zhang et al (35) have shown a positive correlation between 
PTTG levels and the invasiveness of pituitary tumors. 
Interesting effects of PTTG on cellular proliferation have been reported, 
Pei et al have shown that overexpression of PTTG in NIH3T3 cells slows down 
the rate of cell proliferation, which is in contrast to the function of an oncogene 
21 
Figure 6: PTTG up-regulates p53 transcription and its own expression. 
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Figure 6 
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(26). Data from our laboratory and others have since shown that PTTG 
overexpression results in cell cycle arrest and apoptosis (40,66,74), and these 
effects are mediated through bothp53 dependent and independent pathways. 
PTTG overexpression also induces the expression of the Bax protein a 
known target of p53 (74). However, in another study where inducible PTTG 
constructs were used, there was an increase in cell proliferation due to increases in 
c-myc and MEKI expression (73). Altogether it seems that both cell proliferation 
and inhibition of cell proliferation may be a function of cellular PTTG levels. 
When PTTG levels are modestly increase~ cell proliferation is stimulated, while 
the converse is seen when PTTG levels are high. 
Data from our laboratory (Malik et al; unpublished data) and others (75) 
have shown that media from PTTG over-expressing cells promotes angiogenesis. 
Many growth factors including bFGF, EGF, TGF-a and IGF-I in turn increase 
PTTG expression in human cultured cell lines (33,76,77). It is not clear how 
these growth factors increase PTTG expression, but increases in either PTTG or 
growth factors result in enhanced expression of both. There is a positive feedback 
of PTTG and growth factors, suggesting that PTTG and growth factors play 
important complimentary roles in tumorigenesis. Besides these growth and pro-
angiogenic factors, other angiogenic genes such as an inhibitor of DNA binding 3 
(lD3), insulin-like growth factor-I (lGF-I) (76), matrix metalloproteinase-2 
(MMP-2) (Malik et al; unpublished data), interleukin-8 (lL-8) (72), interleukin 10 
24 
(IL-10) and mothers against decapentaplegic, dorsophila, homolog of 1 (SMAD-
1) are expressed after overexpression of PTTG in thyroid cells (76,78,79). 
Decreases in expression of anti-angiogenic genes including thrombospondin-1 
(TSP1), endostatin (42), and tissue inhibitor of metalloproteinases 2 (TIMP2) 
have been observed (Malik et al unpublished data) 
1.6 PTTG GENE REGULATION 
To aid in understanding the mechanisms that regulate the expression of the 
the in tumors, the PTTG gene was cloned Kom a human genomic library (61,62). 
The PTTG gene is composed of six exons and five introns and spans at least 10kb. 
Analysis of the 5' flanking region of the PTTG gene revealed that there is no 
TATA box sequence within 25-35 nucleotides upstream of the putative 
transcriptional start site. However, a CAAT box sequence at -474 bp from the 
transcriptional start site was identified (80). In addition, a number of 
transcriptional binding sites were identified including API, AP2, PEA3, SPI, 
IRE, CHR (cell cycle homology region), CDE (cell cycle-dependent element), 
CRE, ERE and NF-Y (34,46,80) (Figure 7). Recently our laboratory identified 
Sp1 and NF-Y DNA binding sites in the PTTG promoter sequence. Sp1 increases 
the PTTG promoter activity using luciferase reporter assays (81), whereas in the 
presence of DNA damaging agents, p53 suppresses the expression of PTTG in an 
NF -Y dependent manner (82). 
25 
Figure 7: PTTG gene 5' flankiRg sequence. Various transcriptional 
regulatory sequences are highlighted. Inverted triangles represent translational 
start codon ATG. 
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Figure 7 
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It has been established that PTTG expression correlates with 
tumorigenesis; however, the signaling pathways that regulate expression and 
tumorigenesis have not been defined. Tfelt-Hansan et al (77) reported regulation 
of PTTG expression in human astrocytes cells by two promaglinant mitogens, 
epithelial growth factor (EGF) and TGF-a. Data from our laboratory and others 
have demonstrated that both insulin and IGF-I regulate the expression ofPTTG in 
breast tumor cell lines (76,79). The effects of insulin and IGF-I were found to be 
mediated through activation of the Akt pathway, a downstream signaling pathway 
common for insulin and IGF-I (Figure 8). Therefore, it is possible that insulin and 
IGF-I regulated pathways contribute to the-growth and proliferation of tumors by 
activating oncogenic molecular targets such as PTTG. Taken together thses data 
strongly suggests an important role of PTTG in cell proliferation and 
tumorigenesis. 
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Figure 8: IGF I Insulin and EGF regulate the expression ofPTTG through insulin 


























1.7 ANIMAL AND CELL CULTURE MODELS 
To understand the importance of PTTG in vivo, Melmed et al (83) 
generated mice lacking PTTG (PTTG -1-) and showed that such animals exhibited 
aberrant cell cycle progression, premature centromere division chromosomal 
instability, as well as tissue specific phenotypes, such as testicular and splenic 
hypoplasia and thymic hyperplasia (83). In their extended studies these 
investigators showed that male mice lacking PTTG (PTTG-I-) in late adulthood 
showed impaired proliferation of ~-cells and developed type-I diabetes at their 
later adult hood, suggesting the importance of PTTG in ~-cells proliferation and 
insulin production (64). The function of PTTG in tumorigenesis was 
demonstrated by the PTTG(-I-)/Rb(+I-) animal that showed reduced pituitary cell 
proliferation and pituitary tumors (84). On the other hand, Abbud et al (85); 
generated transgenic animals driving the PTTG expression under the control of (J.-
GSU-promoter and showed that transgenic male mice develop pituitary adenomas 
and prostate hyperplasia due to increase in luteinizing hormone (LH) secretion 
(85). We developed tissue specific trans gene mice that expressed PTTG under the 
control of murine inhibitory substance 2 receptor (MISIIR) gene promoter to 
target ovarian surface epithelium. This transgenic animal developed cystic 
glandular hyperplasia of endometrium, and generalized hypertrophy of the 
myometrium. There were no visible ovarian tumors in these transgenic female 
mice (Shahenda et aI, unpublished data). These studies clearly demonstrate that 
PTTG playa critical role in cell proliferation and tumorigenesis. 
31 
1.8 EFFECT OF DOWNREGULATION OF PTTG 
As described earlier, overexpression of PTTG in mouse fibroblast cells 
increases cell proliferation, induces cellular transformation, and promotes tumor 
formation in nude mice (24,27). These results suggest that there may exist a 
relationship between the level of PTTG and tumorigenesis. Based on these results 
we and others hypothesized that down regulation of PTTG mRNA levels should 
inhibits tumor cell proliferation and reverse the cancer phenotype. Use of small 
interfering RNA (siRNA) technology (86), and adenovirus mediated siRNA (87) 
or antisense oligodeoxynucleotides (anti-ONDs) (86,88) are well established 
techniques to reduce the expression of a specific gene. To demonstrate the 
possibility that down regulation of PTTG may reverse the cancer phenotype and 
PTTG may serve as a molecular target for cancer treatment, Kakar and Malik (54) 
showed that transfection of lung tumor cells with PTIG specific siRNA resulted 
in a significant reduction in PIIG mRNA, and protein. Furthermore, these 
transfected cells also demonstrated reduction of both colony formation on soft 
agar and tumor formation in nude mice. siRNA effects are short-lived. Therefore, 
to study the function of PITG and MMP-2 expression and secretion, we used a 
human colorectal cancer cell line (HCTl16), in which both the copies of PTTG 
gene are inactivated genetically by homologous recombination (PTTG -/-
HCTl16) cell (89). More details of this study are explained in chapter IV. 
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In summary, cancer is the leading cause of death in the United States. It 
has been established that tumorigenesis is a multistep process, involving 
activation of proto-oncogenes, growth factors and their receptors and inactivation 
of tumor suppressor genes. Abnormal expression of a gene in tumor cells can be 
associated with several of characteristics that distinguish these cells from normal 
cells. These characteristics includes altered cell differentiation, DNA repair, cell-
cell communication, cell matrix interaction, tumor invasion, migration, 
metastasis, angiogenesis and apoptosis. Our lab cloned a potent oncogene 
pituitary tumor transforming gene (PTTG) from human testis. The PTTG cDNA 
is composed of 656 nucleotide and encodes a protein of 202 amino acid with no 
homology to other known proteins. Over-expression of PTTG in mouse fibroblast 
NIH3T3 cells resulted in increased cell proliferation and induced cellular 
transformation. Furthermore, injection of PTTG stably transfected NIH3T3 cells 
into nude mice resulted in tumor formation, suggesting a role for PTTG in 
tumorigenesis. PTTG may induce its tumorigeneic function through increased 
bFGF, VEGF, and IL-8 expression and secretion. With the exception of testis and 
fetal liver, the levels of PTTG are either very low or undetectable in normal 
tissue. The PTTG is expressed at high levels in almost all tumors including ovary, 
kidney, pituitary, breast, uterus, liver and testis. There are two more members of 
PTTG family, PTTG2 and PTTG3. All three members of PTTG family are 
differentially expressed in normal and tumor tissue. PTTG 1 has been most 
extensively studied. Down regulation of PTTG by siRNA results in loss of cell's 
tumorigeneic function. 
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1.9 HYPOTHESIS AND SPECIFIC AIMS 
There is compelling evidence in the literature to suggest that PTTG is a 
proto-oncogene overexpressed in most tumors and tumor-derived cell lines. 
Overexpression of PTTG inhibits chromatid separation leading to genetic 
instability and ultimately tumorigenesis (45). Studies have shown that transient 
expression of PTTG in mouse fibroblast NIH3T3 cells increases the expression 
and secretion of VEGF and bFGF, (27,90) potent mitogens in angiogenesis 
(91,92). PTTG also possesses transactivation activity, which is related to its 
transformation ability, suggesting a role in regulating the transcription of target 
genes that can regulate its function (47,57). Taken together these results suggest 
that PTTG is a multifunctional protein and mediates its functions through multiple 
signaling pathways. All functional studies of the oncogenic properties of PTTG 
have been performed using mouse fibroblast cells (NIH3T3) (29,35), an ideal cell 
line for studying the behavior of oncogenes and tumor suppressor genes because 
of its indefinite growth in culture, retention of contact inhibition, and ease of 
transformation (93). Due to biological differences between human and rodent 
cells, however, care must be taken in extrapolating results obtained using rodent 
cells to human cells. There are many examples in which overexpression of an 
oncogene can induce transformation of primary rodent cells, but fails to induce 
transformation in human counterpart. Therefore, it is important to test the 
oncogenic abilities of PTTG in human cell line to establish its role in human 
tumorigenesis. 
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1.10 SPECIFIC AIMS 
SPECIFIC AIM 1: 
To determine the role of PTTG in human tumorigenesis using human 
immortalized cell line. 
RATIONALE 
Overexpression of PTTG in mouse primary cells induces cellular 
transformation and promotes tumor formation without the co-operation of other 
genes. Data from our lab and others (24,27) have shown that over-expressing 
PTTG in mouse NIH3T3 cells increased cell proliferation and cellular 
transformation in vitro, and promoted tumor formation in vivo. PTTG over-
expression is also known to induce expression ofbFGF and VEGF (90). Increased 
expression of bFGF and VEGF has been reported in several human tumors and is 
considered to be stimulating for angiogenesis (94). However, whether PTTG 
transforms human cells has not been demonstrated. Major biological differences 
between human cells and rodent cells make it difficult to extrapolate the results 
from rodents to humans (95). There are a number of instances where over-
expression of oncogene in rodent cells fails to transform human cells (96,97). 
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SPECIFIC AIM: 2 
To determine the role of PTTG in up-regulation and secretion of 
metalloproteinases in tumor angiogenesis and metastasis. 
RATIONALE 
PTTG has been reported to increase levels of angiogenic and metastatic 
factors including bFGF and VEGF (27,90). In limited studies of colorectal and 
pituitary adenocarcinomas, a relationship between PTTG expression and 
metastasis has been reported (33,68). However, the mechanism by which PTTG 
regulates metastasis remains unclear. For a tumor to metastasize, many degrading 
proteinases must be activated to facilitate movement of tumor cells from the 
primary site to invade distance sites and metastasize. Matrix metalloproteinases 
(MMPs) are known to play a key role in such processes by degrading the 
extracellular matrix and controlling activities of growth factors, chemokines and 
cytokines that favor tumor metastasis (98). We hypothesized that regulation of 
tumor angiogenesis and metastasis is controled by PTTG by regulating the 
expression and secretion of matrix metalloproteinases. 
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SPECIFIC AIM: 3. 
To determine if decreased PTTG expression in cancer cells reverses the 
cancer phenotype and reduces angiogenesis and metastasis through down 
regulation of metalloproteinases. 
RATIONALE 
PTTG is a potent oncogene that promotes tumor formation in nude mice. 
PTTG has also been shown to regulate the ~xpression of many growth factors and 
cytokines induding bFGF, VEGF, and IL-8 (72). These factors are key regulators 
of tumor angiogenesis and metastasis. PTTG increases the expression and 
secretion of MMP-2. MMP-2 is known to be implicated in the aggressive and 
metastatic tumor phenotypes with poor survival outcomes. If PTTG is essential in 
regulating angiogenesis and metastasis, we perdict deletion of PTTG will reverse 
the cancer phenotype remain unknown. In our study, we will deplete the 
expression ofPTTG by using specific siRNA or will use HCTl16 (PTTG -1-) null 
cell line where the PTTG gene is inactivated by homologous recombination, and 
its counterpart wild type HCT116 (PTTG +1+) as a control to study the effect of 





GROWTH FACTORS AND CYTOKINES 
Growth factors and cytokines are. small secreted molecules. That activates 
signaling cascades in target cells by binding to specific cell specific surface receptors. 
Two types of receptor are important: receptor tyrosine kinases and G-protein-coupled 
receptors. The action of growth factors is mainly mediated through receptor tyrosine 
kinases (RTK) while cytokines act through G-protein-coupled receptors (GPCR). 
These mediators influence cell proliferation in a positive or negative manner by 
inducing a series of intracellular signaling cascades that regulate diverse biological 
responses. Cytoplasmic molecules that mediate these responses are called second 
messengers. Among the intracellular signaling proteins are kinases, phosphates, GTP-
binding proteins. The ultimate transmission of these signals to the nucleus effects the 
expression of many genes involved in mitogenic and differentiation response. 
Pathogenic expression of critical genes in response to constitutive expression of 
growth factors and cytokines can contribute to altered cell growth associated with 
malignancy (99). Almost all tumors can activate the angiogenic switch by changing 
the balance of 
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angiogenic inducers such as growth factors and cytokines required to sustain neo-
vascularization. These growth factors include bFGF, VEGF, IL-8, IL-1O and 
countervailing inhibitors such as thrombospondin-l (98,100,101). 
Cancer development is a complex and multi-step process that involves 
activation of oncogenes, growth factors, and their receptors, or deregulation of tumor 
suppressor genes, leading to abnormal cellular processes. The growth and proliferation 
of cells requires heterotypic mitogenic growth signaling, i.e. growth factors are 
synthesized by one cell type in order to stimulate the proliferation of another cell type 
(14). Instead, cancer cells acquire the ability to synthesize growth factors to which 
they are responsive to, thus creating a positive feedback signaling loop. This autocrine 
signaling obviates the dependence of cancer cell on growth factors from other cells 
and provides growth signal autonomy. In this manner cancer cells modulate external 
and internal signals that regulate their uncontrolled proliferation and evade apoptosis 
(14,100). Furthermore, all mammalian cells are programmed for a limited number of 
cell divisions cycles, which must be disrupted in cancer cells in order to expand to a 
macroscopic size beyond 1 - 2 mm. Cancer cells, may continue to proliferate until 
their oxygen and nutrient supply is limited by access to the vasculature. Thus, 
angiogenesis is a crucial factor in the progression of tumor growth. During 
angiogenesis, tumors activate an angiogenic switch by shifting the balance of gene 
transcription towards angiogenesis inducers, such as growth factors and cytokines, and 
countervailing angiogenesis inhibitors (98). Many tumors increase the expression of 
vascular endothelial growth factor (VEGF), interleukin-8 (IL-8) and acidic and basic 
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fibroblast growth factors (FGF 1 and 2), while expression of endogenous inhibitors 
thrombospodin-l or p-interferon is decreased (78). Basic fibroblast growth factor 
(bFGF) and vascular endothelial growth factor (VEGF) (102,103) are strong mitogens 
for endothelial cells and have been reported to play an essential roles in angiogenesis, 
and stimulation of cell migration and metastasis (104-108). Interleukin-8 (IL-8) 
belongs to a super-family of CXC chemokines, and is a multifunctional cytokine that 
exhibits potent angiogenic and pro-inflammatory activities both in vitro and in vivo 
(109). 
Data from our laboratory (24,72) and others (27) have shown that over-
expression of PTTG cDNA in mouse NIH3T3 fibroblast cells increases the 
expression of bFGF and induces cellular transformation and increased cell 
proliferation. Further, stably transfected mouse NIH3T3 fibroblast cells constitutively 
expressing PTTG injected into nude mice produce tumors. However, a role for PTTG 
in transformation of human cells has not been demonstrated. 
There are discrepancies between mouse and human carcinogenesis (95,110). 
Despite similarities between mouse and humans, murine models of human 
carcinogenesis are questionable due to differences in environmental conditions, 
metabolic stability, and the robustness of the cellular regulatory network (111). Major 
biological differences between human and rodent cells make it difficult to directly 
extrapolate the results from mice to human (95). There are a number of instances in 
40 
which over-expression of oncogenes transformed rodent cells but failed to transform 
the same cells from humans (96,97). 
To determine the role of PTTG in human tumorigenesis, we used the human 
embryonic kidney cell line (HEK293) in our studies as a model. The cell line was 
transformed by human adenovirus type 5 to prevent senescence (112). This cell has a 
moderate tumorigenic potential and have been extensively used to study the oncogenic 
potential of a number of genes (113-115). Mice xenografted with these cells do not 
develop tumors, even three months after injection (115). 
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SECTION II 
Ectopic expression of PTTG/Securin promotes tumorigenesis in 
human embryonic kidney cells. 
2.2 SUMMARY 
Pituitary tumor transforming gene (PTTG) encodes a protein that is primarily 
involved in the regulation of sister chromatid separation during cell division. The 
oncogenic potential of PTTG has been well characterized in the mouse, particularly 
mouse fibroblast (NIH3T3) cells, where it induces cell proliferation, promotes tumor 
formation and angiogenesis. To determine if PTTG functions as an oncogene in 
humans, we have characterized its effects on human embryonic kidney (HEK293) 
cells. We found that introduction of human PTTG into HEK293 cells through 
transfection with PTTG cDNA resulted in increased cell proliferation, anchorage-
independent growth in soft agar, and formation of tumors after subcutaneous injection 
of nu/nu mice. Pathologic analysis revealed that these tumors were poorly 
differentiated. Analyses of HEK293 cells transiently transfected with PTTG cDNA 
and tumors developed after injection of HEK293 cells stably transfected with PTTG 
cDNA indicated significantly higher levels of secretion and expression of bFGF, 
VEGF and IL-8 compared to HEK293 cells transfected with pcDNA3.1 vector or 
uninvolved tissues collected from the mice. Mutation of the proline-rich motifs at the 
C-terminal region of PTTG abolished its oncogenic properties. Mice injected with this 
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mutated PTTG either did not form tumors or formed very small tumors. These results 
suggest that PTTG is a human oncogene that possesses the ability to transform human 
without cooperation of other oncogenes in part through regulation of expression or 
secretion ofbFGF, VEGF and IL-8. 
2.2.1 INTRODUCTION 
Pituitary tumor transforming gene (PTTG), a recently characterized oncogene, 
was initially identified on analysis of a rat pituitary tumor (26); subsequently, a human 
homologue ofPTTG was cloned by us and others (24,27,29). Three members (PTTG, 
PTTG2 and PTTG3) of the PTTG family, which exhibit differential expression in 
normal and tumor cells have been reported (30), although only PTTG has been studied 
in detail. PTTG is located on chromosome 5q33 (61), a locus associated with 
recurrent lung cancer and myelogenous leukemias (62). Moreover, it has been shown 
to be expressed highly in various tumors, and cell lines derived from such tumors, 
including tumors of the pituitary, thyroid, colon, ovary, testicles and breast (25,33,68-
70). In normal tissues, its expression is low or undetectable except in testis (24,26). 
Recent studies have indicated that elevated expression of PTTG in some tumors may 
serve as a prognostic marker for tumor invasiveness and metastasis (36). A clue to its 
function was gained from its structural similarity with the yeast securin, which led to 
its identification as a human securin (45), and suggested that it may play a role in 
regulation of sister chromatid separation. It appears, to have multiple effects in cells 
including enhanced expression associated with an increase in the expression of the c-
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myc oncogene (73), an increase in the expression of p53 (40,74), an increase in the 
secretion and expression of basic growth factor (bFGF) (75), and an increase in the 
secretion and expression of vascular endothelial growth factor (VEGF) (75,90). 
To date, evidence for the oncogenic function of PTTG has been obtained by 
overexpression of PTTG in mouse fibroblast cells (NIH3T3) followed by assessment 
of its ability to induce cellular transformation in vitro (colony formation in soft agar) 
and tumor formation in nude mice (24,27). Due to differences between human and 
rodent cells, care must be taken in extrapolating results obtained using rodent cells to 
human cells. There are now several examples in which overexpression of an 
oncogene induces transformation of primary rodent cells(96), the same strategy failed 
to induce transformation of the same cell type derived from humans. Usually this 
failure is attributable to the requirement for co-expression of another gene or 
oncogenic cooperation of other genes (116-120). 
Similarly, much of the evidence concerning the mechanisms by which PTTG 
may affect the phenotype of the cell has been obtained using transfected NIH3T3 
cells. It is known that the secretion of growth factors and cytokines by tumor cells, 
and the cells that infiltrate and surround the tumor mass play an essential role in the 
regulation of tumor growth and metastasis (121). Both bFGF and VEGF have been 
implicated in tumorigenesis and the expression and secretion of these molecules has 
been demonstrated on transfection of NIH3T3 cells with PTTG cDNA (75,90), but 
this has not been confirmed with transfection of human cells. The effect of PTTG 
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expression on another cytokine that is known to play a key role in tumorigenesis, 
interleukin-8, (IL-8), have not yet been analyzed. 
The purposes of this study were three-fold. First, to determine whether PTTG 
can induce cellular transformation of normal human cells; second, to determine if 
PTTG is sufficient to induce transformation; and, third, to characterize changes in 
secretion and expression of key metastatic, angiogenic and chemokine factors (bFGF, 
VEGF and IL-8). For these studies, we selected the human embryonic kidney 
(HEK293) cell line as our model. The expression of the SV40 large T antigen by 
these cells prevents their senescence, but they do not exhibit tumorigenic 
characteristics nor do they develop into tumors when xenografted into nude mice 
(120,122). 
2.2.3 MATERIAL AND METHODS 
Generation of cell lines constitutively expressing PTTG: 
The human embryonic kidney cell line (HEK293), which had been transfected 
previously with SV 40 large-T antigen, was purchased from ATCC (American Type 
Culture Collection; Rockville, MD) and cultured according to the instructions 
provided. The cells were transfected with pcDNA3.1 vector, pcDNA3.1-PTTG or 
pcDNA3 .1-mPTTG to generate stable clones that constitutively express human wild-
type PTTG or mutated PTTG (mPTTG) protein as described previously (24). The 
mPTTG, which carries a double amino acid change within the SH3 binding domain of 
45 
PTTG (p163 to A163, p170 to A170 and p172 to A172, and p 173 L173), was generated by site-
directed mutagenesis using the Quick-change mutagenesis kit (Stratagene, La Jolla, 
CA) according to the manufacturer's instructions. Mutation of these amino acids has 
been reported to abrogate the tumorigenic function of PTTG and to block the secretion 
and expression of bFGF in mouse NIH3T3 cells (27). The primers used for this site-
directed mutagenesis were 5' -GATGCTCTCCGCACTCTGGGAA TCCAATCTG-3' 
and 5'-TTCACAAGTTGAGGGGCGCCCAGCTGAAACAG-3'. The transfected 
cells were then selected in neomycin G418 (500 J..lg/ml) and the clones that expressed 
high levels of PTTG protein or mPTTG protein were selected. One clone from 
pcDNA3.l transfected cells (HEKpcDNA3.l) two clones from pcDNA3.l-PTTG 
transfected cells (HEKPTTG-l and HEKPTTG-3) and two clones from pcDNA3.l-
mPTTG transfected cells (HEKmPTTG-2 and HEKmPTTG-4) were propagated into 
cell lines. 
Cell proliferation assay: 
Cell proliferation was assayed using the CellTiter 96 non-radioactive cell 
proliferation assay kit (Promega, Madison, WI) according to the manufacturer's 
instructions and as described previously (24). Briefly, cells growing in log phase were 
trypsinized and seeded in 96-well plates (5,000 cells/well in a final volume of 100 J..lI) 
in replicates of 4 and incubated at 370 C in 5% CO2 and 95% air. After incubation for 
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24 h, 48 h, 72 h or 96 h, 20 j.ll of dye solution from the kit was added to each well and 
incubated at 37° C for an additional 2 h. The quantity of formazan product was 
measured by its absorbance at 490 nm using a 96-well plate reader (Molecular 
Devices, Sunnyvale, CA). Each experiment was repeated at least three times. 
Soft agar colony formation (anchorage-independent cell growth) assay: 
Anchorage-independent cell growth was determined by analyzing the 
formation of colonies in soft agar. Cells (104) from each cell line were suspended in 
0.3% agar in DMEM containing 10% fetal bovine serum and plated on solidified agar 
(0.7%) in 35 mm dishes. After 14 days of culture, colonies formed were counted and 
photographed as described previously (24). 
In vivo tumor growth assay: 
Cells growing in log phase were harvested by trypsinization and washed twice 
with PBS. The cells were resuspended in PBS to a final concentration of 5x106/ml. 
The cells (lx106 cells in 200 j.ll PBS/site) were injected subcutaneously (s.c.) into both 
flanks of 5- to 6-week old female nu/nu mice (4 mice/group) (Charles River 
Laboratory, Wilmington, MA). All procedures were carried out following the protocol 
approved by The University of Louisville Institutional Animal Care and Use 
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Committee. Four weeks after injection, the mice were sacrificed, and the tumors and 
other tissues harvested. The skin and connective tissues were dissected from the 
tumors, and the tumor volume was calculated from measurements of length x width x 
height. The tissues were divided into two parts, one part being fixed in 10% buffered 
formalin and the other stored in liquid nitrogen. For histopathologic analysis, 51lm 
sections were cut from paraffin-embedded tissues, and mounted on slides. Sections 
were stained with H&E (123), and processed for histopathologic evaluations. 
Western blot analysis: 
Cells growing in log phase were lysed in chilled lysis buffer [50 mM Tris-HCl 
(pH 7.5), 150 mM NaCl, 1% NP-40, 1 mM Na3V04, and 1 mM NaF] supplemented 
with Complete Mini Protease Inhibitor tablets (Roche Molecular Biochemicals, 
Indianapolis, IN). Equal amounts of protein extract (40llg) were resolved on 12% 
SDS-PAGE gel, and transferred onto a nitrocellulose membrane (Amersham, 
Piscataway, NJ). Blots were probed with PTTG antiserum at a dilution of 1: 1 ,500 as 
described previously (124). Immunoreactive proteins were visualized using the 
Enhanced Chemiluminescent Detection System (Amersham) according to the 
instructions provided. 
ELISA analysis ofbFGF, VEGF and IL-8 
The levels of bFGF, VEGF and IL-8 in tissue culture supernatants and tissue 
homogenates were measured using commercially available ELISA kits from BD 
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Biosciences (Minneapolis, MN). To measure bFGF, VEGF and IL-8 in the culture 
supernatants, HEK293 cells were transiently transfected with pcDNA3.1 or 
pcDNA3.1-PTTG cDNA using Fugene6 as the transfectant reagent as described 
previously (81). After 24 h of transfection, the medium was replaced with serum free 
DMEM medium. Twenty-four hr later, the medium was collected and concentrated 5-
fold (1.0 ml to 200 Ill) using a speedVac system (Savant, Holbrook, NY). To measure 
bFGF, VEGF and IL-8 in tumor and other tissues, tissues were homogenized in 50 
mM Tris (pH 7.4), 0.25% Triton X-IOO, 5 mM EDTA and 0.1% NP40 supplemented 
with Complete Mini Protease Inhibitor tablets (Roche Molecular Biochemicals, 
Indianapolis, IN) using a polytron homogenizer. Homogenates were centrifuged to 
remove particulate matter and then diluted with the diluent provided in the ELISA kit. 
The concentration of bFGF, VEGF and IL-8 in a sample was determined by 
interpolation from a standard curve. All measurements were normalized to protein 
concentration and performed in triplicate. 
Semi-quantitative reverse transcriptase/polymerase chain reaction (RTIPCR): 
Total RNA from tumors and other tissues was purified using Trizol reagent 
(Invitrogen, Carlsbad, CA) following the manufacturer's instructions. The RNA 
pellets were resuspended in RNase-free water and the contaminating DNA was 
removed from the preparations with DNase!. The yield of total RNA was measured 
using a spectrophotometer and the quality was assessed by electrophoresis through a 
1 % agarose gel. First strand cDNA was synthesized using the iScript™ cDNA 
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synthesis kit (BioRad, Hercules, CA). PCR primers Cfable 1) were designed based on 
the human PTTG, bFGF, VEGF and IL-8 cDNA sequences. The PCR conditions for 
each gene are listed in Table 1.GAPDH amplification was used as an internal control. 
Ten III from a total of 50111 PCR reaction mix was applied to a 2% agarose gel and 
after electrophoresis; the gel was stained with ethidium bromide to visualize PCR 
products. The densitometric values for the PCR-amplified products were quantified 
using BioRad software and normalized against the GAPDH values. 
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Table 1: Primer sequences and peR conditions for the amplification of PTTG, bFGF, 
VEGF, IL-8 and GAPDH. 
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Table 1 
Sense Primer Antisense Primer 
Sequence Sequence PCR Conditions 
PTTG ATGGCTACTCTGAT AAAATCTATGTCAC 
95°C 5 min, 95°C 30 
CTAT AGCAAAC s, 54°C 30 s, 72°C 30s. 28 cycles. 
bFGF TTCTTCCTGCGCAT CTCTTAGCAGACAT 
95°C 5 min, 95°C 30 
CCACCC TGGAAG s, 56°C 30 s, 72°C 30s. 26 cycles. 
VEGF GAATCATCACGAA AACGCGAGTCTGTG 
95°C 5 min, 95°C 30 
GTGGTGA II II IG s, 56°C 30 s, 72°C 30s. 28 cycles. 
IL-8 ACCACCGGAAGGA GAATTCTCAGCCCT 
95°C 5 min, 95°C 30 
ACCATCT CTTCAA s, 58°C 30 s, 72°C 30s. 28 cycles. 
GAPDH TGATGACATCAAG TCCTTGGAGGCCAT 
95°C 5 min, 95°C 30 
AAGGTGGT GTGGGCC s, 54°C 30 s, 72°C 30s. 26 cycles. 
Mutated- GATGCTCTCCGCAC TTCACAAGTTGAGG 95°C 5 min, 95°C 30 
PTTG TCTGGGAATCCAAT GGCGCCCAGCTGA s, 54°C 30 s, 72°C CTG AACAG 30s. 35 cycles. 
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2.2.4 RESULTS 
Generation of HEK293 cells stably expressing PTTG and mPTTG: 
HEK293 cells were transfected with pcDNA3.l-PTTG, pcDNA3.l-mPTTG or 
pcDNA3.1 vector. After G418 selection, 10 clones from each of pcDNA3.l, 
pcDNA3.l-PTTG or pcDNA3.l-mPTTG transfected cells were picked, cultured, and 
expanded. The PTTG protein expression of these transfectants was detected by 
western blot analysis using PTTG antiserum. Two representative clones from PTTG 
transfected (named HEKPTTG-1 and HEKPTTG-3) and mPTTG transfected (named 
HEKrnPTTG-2 and HEKrnPTTG-4), and one clone from pcDNA3.1vector (named 
HEKpcDNA3.1) was selected for further studies. Selection of clones was based on the 
level of expression of PTTG protein. (Figure 9) shows the protein expression of these 
clones. Transfection of cells with the pcDNA3.1 vector resulted in expression of a 
very low level ofPTTG protein. The clones of the pcDNA3.1-PTTG- and pcDNA3.l-
mPTTG-transfected cells that exhibited approximately equivalent levels of expression 
of PTTG and mPTTG proteins were processed to establish stable cell lines. 
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Figure 9: Western blot analysis of HEK293 cells transfected with pcDNA3.l, 
pcDNA3.l-PTTG or pcDNA3.1-mPTTG. a: HEK pcDNA3.l, b: HEK PTTG clone 1, 
c: HEK PTTG clone 3, d: HEK m-PTTG clone 2, and e: HEK m-PTTG clone 4. 
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Figure 9 
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PTTG'" 
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Stable transfection of PTTG induces cell proliferation and transformation of 
HEK293 cells overexpressing PTTG. 
Previously we have shown that over-expression of PTTG in mouse fibroblast 
NIH3T3 cells results in an increase in cell proliferation (24). To determine if over 
expression of PTTG in HEK293 cells produces similar effects, we estimated the 
proliferation at 24, 48, 72 and 96 hours after plating of stably transfected HEK293 
cells expressing high levels of PTTG or mPTTG protein. Both clones of PTTG-
transfected cells (HEKPTTG-1 and HEKPTTG-3) exhibited significantly greater 
proliferation than the cells transfected with vector only at all time points tested, and 
the time course of proliferation was very similar in both clones, increasing by 30-40% 
after 24 hours, 40-50% after 48 hours, 60-80% after 72 hours and 110-130% after 96 
hours (Figure 10). Surprisingly, the proliferation of the cells expressing the mutated 
PTTG was equivalent to that of the cells expressing the wild-type PTTG and was 
significantly higher than that of the cells transfected with vector only. These 
experiments indicate that over expression of PTTG induces a significant proliferative 
effect in HEK293 cells; however, at least under the conditions used, mutation of the 
proline-rich motifs of PTTG did not affect this response. 
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Figure 10: Cell proliferation of HEK293 cells stably transfected with pcDNA3.l, 
PTTG 1 or mPTTG 1. 5 x 103 cells were plated / well. The results are expressed as 
percent of control (HEK293 cells stably transfected with pcDNA3.l control vector). 
Error bars ± SEM (n = 4) of three independent experiments. p<0.05 
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Overexpression of PTTG induces cellular transformation. 
Next, we assayed the effects of transfection with PTTG on the ability of the 
HEK293 cells to form colonies in soft agar (anchorage-independent growth). As 
shown in (Figure 11), over-expression of PTTG in HEK293 cells resulted in a higher 
incidence of colony formation than that observed on transfection with the vector only. 
The cells transfected with vector only formed few colonies and these were of small 
size during 14 days of culture, whereas both the cell lines expressing wild type PTTG 
formed a significantly higher number of colonies, which were of a large size. The 
incidence of colony formation was 2% for HEKpcDNA3.l cell line but was 19% for 
the HEKPTTG-l cell line and 30% for the HEKPTTG-3 cell line. In this case, 
mutation of the proline-rich motifs of PTTG resulted in a significant reduction in the 
number of colonies formed with the incidence of colony formation for the 
HEKmPTTG-2 and HEKmPTTG-4 cell lines being similar to the vector-only 
transfected cells (HEKpcDNA3.l). These results suggest that over expression of 
PTTG in HEK293 cells induces cellular transformation, and mutation of proline-rich 
motifs does not effect the cell proliferation, but abrogates the cellular transformation 
ability of PTTG. 
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Figure 11: Colony formation of HEK293 cells stably transfected with pcDNA3.l, 
pcDNA3.l-PTTGl or pcDNA3.1-m-PTTGl. a: HEK pcDNA3.1, b: HEK PTTGl, c: 




PTTG induces tumor formation in nude mice injected with HEK293 cells stably 
expressing PTTG protein. 
To determine whether PTTG promotes tumor formation in nude mice, we 
subcutaneously injected nude mice with HEK293 cells expressing PTTG or mPTTG. 
Three out of four mice injected with the HEKPTTG-1 or HEKPTTG-3 cell lines 
developed large tumors within four weeks of injection (Figure 12). Pathologic analysis 
of the tumors revealed that they were poorly differentiated (Figure 13). Mice injected 
with the HEKmPTTG-2 cell line also developed tumors, but the tumors were of a 
small size. None of the mice injected with the other cell line-expressing mutant PTTG 
(HEKmPTTG-4) or the vector-only cell line (HEKpcDNA3.1) developed tumors 
within the time frame of this experiment. The tumor volumes, measured at the end of 
experiment (six weeks after injection of cells), were 150-1320 mm3 for HEKPTTG-1, 
72-1404 mm3 for HEKPTTG-3 and 8.8-12.6 mm3 for HEKmPTTG-2 (Table 2). 
These results clearly demonstrate that PTTG gene is a potent oncogene. 
Moreover, they demonstrate that PTTG possesses the ability to act alone to induce 
transformation of human cells, and does not require the oncogenic cooperation of 
other gene(s) to achieve its tumorigenic function. 
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Figure 12: Tumor development in nulnu mice on injection of HEK293 cells stably 
transfected with pcDNA3.1, pcDNA3.1 PTTG1 or pcDNA3.1 m-PTTG1 plasmids. 
Each mouse was injected with 1 x 106 cells. Six weeks after injection, the mice were 
photographed and sacrificed, tumor and other tissues were collected and tumor 
volumes were measured. a: Mouse injected with HEK pcDNA3.1 cells, b: mouse 
injected with HEK pcDNA3.1 PTTG1 cells, c: mouse injected with HEK pcDNA3.1 
PTTGl-3 cells, and d: mouse injected with HEK pcDNA3.1 m-PTTGl-2. Arrows 




Figure 13: Histopathological analysis of the tumors excised from animals injected with 
HEK293 expressing PTTG 1 or m-PTTG I. a: Normal HEK293 cells stained with 
hematoxylin, b: tumor from animal injected with HEK pcDNA3.l PTTGI, c: tumor 




Table 2: Tumor fonnation induced by PTTG 1 expressing HEK293 cells in nude mice. 
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Table 2 
Clone Animals with Tumor Volume tumor Ran2e 
HEK pcDNA3.1 0/4 NA 
HEKPTTGl-l 3/4 150-1320 mm3 
HEKPTTGl-3 3/4 72-1404 mm3 
HEKm- 2/4 8.8-12.6 mm3 PTTGl-4 
HEKm- 0/4 NA PTTGl-2 
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PTTG stimulates expression and secretion of bFGF, VEGF and IL-S. 
Local invasive growth is a key feature of primary malignant tumors. A 
correlation between the levels of expression of PTTG with increased tumor 
invasiveness and with the degree of malignancy has been demonstrated in pituitary 
and colorectal tumors (33,125). The specific mechanisms by which PTTG facilitates 
the invasive behaviors of tumor cells remain obscure. Recently Melmed et aI, (75,90) 
have shown that transfection ofNIH3T3 cells with PTTG cDNA results in an increase 
in secretion and expression of both bFGF and VEGF. A direct correlation between 
high IL-8 expression and tumor metastases has been shown in a number of cancers 
(109,126,127), and IL-8 also has been reported to possess mitogenic (128) and 
angiogenic effects (129). We therefore measured the levels ofbFGF, VEGF and IL-8 
in HEK293 cells transiently transfected with pcDNA3.1 or pcDNA3.1-PTTG cDNA 
and in tumors developed on injection of nude mice with HEK293 cells that 
constitutively express PTTG. As shown in (Figure 14A), the levels of bFGF, VEGF 
and IL-8 were comparatively higher in conditioned medium of cells transfected with 
pcDNA3.l-PTTG cDNA than from cells transfected with pcDNA3.1 vector only. 
Cells transfected with pcDNA3.1-PTTG showed a 2-fold increase in bFGF, a 3.5-fold 
increase in VEGF and a 2-fold increase in IL-8 levels compared to cells transfected 
with pcDNA3.1 vector only. Measurement of the mRNA levels of these proteins by 
RT/PCR showed significantly higher levels in cells transfected with pcDNA3.1-PTTG 
cDNA 
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Figurel4: Overexpressing of PTTG in HEK293 cells induces secretion and expression 
of bFGF, VEGF, IL-8. HEK293 cells were transiently transfected with pcDNA3.l or 
pcDNA3.l-PTTGl eDNA. The culture media was removed, lyophilized and bFGF, 
VEGF, and IL-8 secreted in culture medium were measured by ELISA. a: amount of 
bFGF, VEGF and IL-8 in culture medium. Vector: cells transfected with pcDNA3.l 
vector DNA; PTTGl: cells transfected with pcDNA3.l-PTTGl eDNA. B: Expression 
of bFGF, VEGF and IL-8 mRNA in cells. Lane l: pcDNA3.1 transfected cells and 
Lane 2: pcDNA3.l-PTTGl transfected cells. GAPDH was used as a loading control. 




































compared to cells transfected with pcDNA3.l vector (Figure 14B). To determine if 
over expression of PTTG results in increase in levels of bFGF, VEGF and IL-8 in 
vivo, we measured the levels of bFGF, VEGF and IL-8 proteins in lysates from tumors 
developed on injection of nude mice with HEK293 cells stably transfected with PTTG. 
As shown in (Figure 15), the levels of bFGF, VEGF and IL-8 were significantly 
higher in three out of four tumors compared to normal tissues (kidney, liver, lung and 
heart) collected from the same animals. Since the size of the tumors that developed on 
injection of cells expressing mutated PTTG (HEKmPTTG-2) were small, we were 
unable to analyze the bFGF, VEGF and IL-8 levels in these tumors. Measurement of 
mRNA for bFGF, VEGF and IL-8 revealed significantly higher levels of expression in 
tumors compared to normal tissues and tumors developed on injection of 
HEKmPTTG-2 cells (Figure 16). bFGF levels were found to be comparatively higher 
in heart which is consistent with other investigators (130) Our results show that over-
expression of PTTG in HEK293 cells resulted in an increased secretion and expression 
ofbFGF, VEGF and IL-8 in vitro and in vivo, suggesting that increase in secretion and 
expression of bFGF, VEGF and IL-8 by PTTG may be one mechanism by which 
PTTG achieves its oncogenic function and increases tumor angiogenesis. 
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Figure 15: Analysis of bFGF, VEGF and IL-8 expression by ELISA. Tumors and 
other tissue were excised from the animals injected with HEK293 cells stably 
transfected with PTTGI (clone 1 and 3) and homogenized. bFGF, VEGF and IL-8 in 
the homogenates were analyzed by ELISA. Each analysis was performed in triplicate 
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Figure 1 6: Analysis of expression of PTTG, bFGF, VEGF and IL-8 from tumors and 
other tissues collected from mice injected subcutaneously with HEK293 cells stably 
expressing PTTGI protein. a: RT-PCR analysis and , b: western blot analysis. Tl: 
tumor 1, T2: tumor 2, M: HEK m-PTTGI-2, H: heart, K: kidney, Li: liver, Lu: Lung. 
GAPDH and p-actin were used as control to examine equal loading. The gels are 










HEK PTTGl-l HEK PTTGl-3 









Tl T2 H K Li Lu 
J3-Actin ?frr"' ' '' "'11;: '" .Jr, t ',r IB,'IL,C" I / 
76 
2.2.4 DISCUSSION 
The oncogenic function of PTTG was established by its overexpression in a 
mouse fibroblast cell line (NIH 3T3) followed by assessment of its ability to induce 
cellular transformation and tumor formation in nude mice (24,27). However, the 
differences in biology between the rodent cells and human cells have brought the 
validity of this model into question. There are a number of instances in which an 
oncogene has been shown to induce transformation in rodent cells but failed to induce 
transformation of the same types of cells obtained from humans. To test the ability of 
PTTG to induce transformation in human cells, we selected the human embryonic 
kidney- 293 (HEK293) cell line as our model. HEK293 cells have been transfected 
with the large-T antigen and the expression of this molecule results in the cells 
bypassing senescence and being immortalized. It has been demonstrated that 
expression of large-T antigen does not convert these cells to the tumorigenic 
phenotype nor do these cells develop tumors when injected into nude mice (120). Our 
data clearly demonstrate that over-expression of PTTG in HEK293 results in an 
increase in cell proliferation, induces cellular transformation invitro (increase in 
anchorage-independent growth), and promotes tumor formation in nude mice. Cells 
transfected with pcDNA3.1 vector did not form colonies in soft agar or develop into 
tumors on implantation in nude mice, confirming that HEK293 cells do not possess a 
tumorigenic phenotype. Thus, our results suggest that PTTG is a potent oncogene and 
is capable of inducing tumorigenesis in human cells. 
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A second issue that we were able to address using the HEK293 cell model is 
the question of the ability of PTTG to induce transformation of normal human cells, 
i.e., whether it acts alone or in cooperation with another oncogene to achieve its 
tumorigenic function. It has been reported that a single oncogene may not be 
sufficient for induction of transformation, but requires co-expression, or oncogenic 
cooperation, of another oncogeneses) to induce tumorigenesis in normal primary 
human cells (96,116,118,119,131,132). Our data clearly show that PTTG is sufficient 
to achieve its tumorigenic function without the cooperation of another gene. 
PTTG contains several-proline rich motifs (PXXP); two of these that are 
located in the C-terminal domain have been reported to be potential binding sites for 
SH3-domians (133). In our study we confirm that mutation of these C-terminal 
proline-rich motifs abrogates the tumorigenicity ofPTTG in human cells. Such loss of 
tumorigenicity on mutation of PTTG could be due to a loss of expression. Our 
western blot analysis of the stable cell lines (HEKmPTT1-2 and HEKmPTTG-4) that 
constitutively express mutated PTTG protein showed high levels of expression of 
mPTTG protein, suggesting that the loss of tumorigenic function of mPTTG protein is 
not due to loss of expression but due to the loss of its ability to induce cellular 
transformation. These results are consistent with other investigators for rodent cells 
(27) and confirm the importance of C-terminal proline-rich motifs to mediate the 
oncogenic function of PTTG. 
The molecular mechanisms by which PTTG achieves its tumorigenic function 
remain unclear. PTTG has been reported to induce expression of the c-myc oncogene 
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(56), bFGF (75) and VEGF (90). bFGF is a broad spectrum and pleiotropic mitogen 
for growth and differentiation affecting various mammalian cells and organ systems 
and a large number of cells lines (134). Besides stimulating wound healing, tissue 
repair and hematopoiesis (135), bFGF induces cell migration and proliferation (91) 
and acts as an agio genic factor that induces migration, proliferation and differentiation 
of endothelial cells (136). In addition, it has been reported to modulate the invasion of 
tumor cells through surrounding tissue to form new capillary cord structures by 
regulating the activities of extracellular molecules including collagenase, proteinases 
and integrins (136). Regulation of secretion and expression of bFGF by PTTG in NIH 
3T3 cells has been shown (27). Consistent with these reports, our results demonstrate a 
significant increase in secretion and expression of bFGF in HEK293 cells on transient 
transfection with PTTG cDNA as well as in tumors developed by injection of stable 
cell lines that constitutively express PTTG. 
VEGF is a potent stimulant of the vascularization of tumors and is one of the 
most specific markers of tumor vasculature observed to date (105,1 06). VEGF is a 
multifunctional cytokine acting as a potent permeability agent, an endothelial cell 
chemotactic agent, an endothelial cell survival factor and an endothelial cell 
proliferation factor (137). The expression and secretion of VEGF has been shown to 
be a crucial rate-limiting step during tumor progression (108). Our results 
demonstrate a significant increase in secretion and expression of VEGF in HEK293 
cells on transfection with PTTG and also from tumors excised from animals injected 
with HEK293 cells that stably express PTTG. 
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A direct correlation between high IL-S expression and metastases in melanoma 
(109), ovarian cancer (126), prostrate cancer (127) and pancreatic cancer (13 S) has 
been reported. To determine if overexpression of PTTG induces change in secretion 
and expression of IL-S, we measured its levels in HEK293 cells on transfection with 
PTTG cDNA and in tumors developed on injection of HEK293 cells transfected with 
PTTG. Our results demonstrate for the first time that overexpression of PTTG induces 
IL-S expression in vitro and also in tumors in vivo. 
In summary, our results demonstrate that PTTG is a potent human oncogene 
and has the ability to induce cellular transformation of human cells. Overexpression of 
PTTG in HEK293 cells leads to an increase in the secretion and expression of bFGF, 
VEGF and IL-S. Mutation of C-terminal proline-rich motifs abrogates the oncogenic 
function of PTTG. To our knowledge, this is the first study demonstrating the 






Metalloproteinases are a multigene family of metal-containing proteases that 
share common structural and functional characteristics. All of the family members 
sequenced to date have at least three common domains: (i) a prodomain which 
contains a conserved cysteine residue that is lost on activation; (ii) a catalytic domain 
which contains a conserved metal-binding site and (iii) a highly conserved zinc-
binding active site (Figure 17) (139). There are at least 24 members of the MMP 
family, and that can be subdivided according to their substrate specificity. Regulation 
of MMPs occurs at three different levels: alteration of gene expression, activation of 
latent zymogens, and inhibition by tissue inhibitors of metalloproteinases (TIMP). 
Among the members of the MMP family, gelatinases (MMP-2 and MMP-9) are the 
most common metalloproteinases associated with tumor metastasis and angiogenesis. 
Overexpression of MMP-2 has been correlated to an invasive phenotype in several 
cancer types and is often predictive of poor survival (140). MMP-2 knockout mice 
display lowered lung colonization following intravenous administration of cancer 
cells, and reduced tumor angiogenesis resulting in 
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reduced tumor growth (141). Moreover, MMP-2 has been shown to be a prognostic 
marker in ovarian cancer, lung cancer, and gastric cancer (142-144). MMP-2 is also 
known to be involved in tumor angiogenesis through degradation of extracellular 
matrix (ECM), which can result in tumor cells, and endothelial cell migration due to 
loss of cell-matrix and cell-cell contacts (145). MMP-2 is also capable of releasing 
growth factors that are from ECM, cleaving certain growth factor receptors and 
activating growth factors, excreted as pre-pro-enzymes, such as transforming growth 
factors (TGFa, TGF~), macrophage-colony stimulating factor (M-CSF), insulin like 
growth factor (IGF), and fibroblast growth factor receptor (FGFR) (146-148). 
However, as the MMP-2 activity may not always lead to angiogenesis and metastasis, 
the mechanisms by which metalloproteinases are regulated remain unclear. 
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SECTION II 
Regulation of Angiogenesis and Invasion by human Pituitary tumor transforming 
gene (hPTTG) through increased the expression and secretion of Matrix 
Metalloproteinase-2. 
INTRODUCTION: 
Primary tumor growth is restricted due to a limited supply of oxygen, nutrients, 
and growth factors. Tumor progression and invasion to distant organs depends on 
tumor angiogenesis. To achieve angiogenesis various factors including transforming 
genes and growth factors turn on to enable tumor progression (44). Once angiogenesis 
is initiated, the tumors expand exponentially and invade to local and distance tissues. 
From a patient survival perspective, understanding the mechanisms of angiogenesis 
and development of new therapeutics to inhibit angiogenesis is a critical step leading 
to inhibition of tumor growth and metastasis (98,99). 
Many oncogenes have been reported to play important role in tumor 
angiogenesis. Recently, a novel oncogene, pituitary tumor transforming gene (PTTG), 
also known as securin, has been reported to playa vital function in tumor angiogenesis 
(90). Using an mRNA differential technique, PTTG was originally cloned from rat a 
pituitary tumor (26), followed by cloning homologue from humans (4-6). The 
predominant cellular location of the PTTG protein is the cytoplasm, although it is 
partially localized in the nucleus (66). Nuclear translocation of PTTG can be 
facilitated by either interaction with PTTG binding factor (PBF) (149), or by 
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interaction with the mitogen-activating protein (MAP) kinase cascade (56). The level 
of PTTG expression is increased in rapidly proliferating cells and is regulated in a cell 
cycle-dependent manner (45). PTTG mRNA and protein expression are low at the 
G liS interphase, gradually increase during the S phase, and peak at the G2/M phase 
(45). As the cells enter anaphase, PTTG is degraded and daughter cells express very 
low amounts ofPTTG. The degradation ofPTTG most likely occurs via ubiquitination 
since PTTG contains a D box which is required for such proteolysis. 
Numerous studies have demonstrated that human PTTG displays a distinct 
pattern of expression. In normal tissues, PTTG expression is restricted, with high 
levels in testis, and low levels in the thymus, colon, and small intestine (24,27). In 
contrast, PTTG is highly expressed in a variety of human primary tumors as well as 
tumor cell lines including carcinomas of the ovary, lung, testis, kidney, colon, thyroid, 
pituitary, liver, adrenal, breast, prostate, melanoma, leukemia, and lymphoma 
(24,25,29,33,36,47,66,80,150-153), suggesting that PTTG may be involved in 
tumorigenesis. Furthermore, the expression level of PTTG correlate with increased 
tumor invasiveness in human pituitary tumors with hormone overproduction (151), 
and with the degree of malignancy, pathogenesis and/or progression of colorectal and 
thyroid tumors (33,151,154). PTTG has been identified as one of eight signature genes 
associated with tumor metastasis and up-regulated in human primary solid tumors 
(36). A relationship between the survival rate and level of expression of PTTG in 
esophageal cancer has been reported (71). 
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We and others have shown that overexpression of human PTTG in mouse 
fibroblasts (NIH3T3) and human embryonic kidney (HEK293) cells results in 
increased cell proliferation, induction of cellular transformation in vitro and formation 
of tumors in nude mice (24,27). Currently, the precise mechanism by which PTTG 
causes cell transformation remains unclear. Data from our laboratory and others 
suggest that PTTG may act through basic growth factor (bFGF) (24,155), vascular 
endothelial growth factor (VEGF) (72,90), and/or interleukin-8 (IL-8) (72). Additional 
mechanisms by which PTTG may induce its oncogenic function are indicated by 
findings that implicate it in sister chromatid separation during cell division (45). 
PTTG, by virtue of its function as human securin, ensures that there is no premature 
separation of sister chromatids. Mice that lack PTTG show aberrant cell cycle 
progression, premature centromere division, and problems with chromosomal stability, 
as well as tissue specific phenotypes, such as testicular and splenic hypoplasia and 
thymic hyperplasia (83). In addition, PTTG null mice exhibit impaired proliferation 
of pancreatic beta cells and developed type I diabetes during late adulthood (64,83). 
Furthermore, animal deficient in PTTG (-/ -) demonstrat inhibition of tumor 
development compared to Rb (+/-) induced tumors (84). On the other hand, transgenic 
animals that express PTTG under the control of the aGSU promoter developed an 
enlarged pituitary and hyperplasia of prostate (85). Taken together, these data strongly 
suggest an important role of PTTG in cell proliferation and tumorigenesis and suggest 
mechanisms that may contribute to these effects. 
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Local invasive growth is a key feature of primary malignant tumors. A 
correlation between the level of expression of PTTG with increased tumor 
invasiveness and degree of malignancy in pituitary and colorectoral tumors has been 
reported (33). However, the specific mechanisms facilitating the invasive behavior of 
cancers remain obscure. Interactions between cancer cells and surrounding normal 
cells and the extra-cellular matrix (ECM) are thought to be key event in tumor cell 
invasion (140,146). To invade and spread through the surrounding normal tissue, 
tumor cells must degrade multiple elements of the ECM, including fibronectin, 
laminin, and type IV collagen (139,156). Several metalloproteinases (MMPs) are 
required for the degradation of the ECM, and these are classified according to their 
substrate specificity. MMP-2 and MMP-9 are the most common MMPs in tumors, and 
the elevated levels have been reported in various cancers (139,157,158). In the present 
study, we show that overexpression of PTTG in HEK293 cells results in up-regulation 
of the secretion and expression of MMP-2, but not MMP-9, leading to increased cell 
migration and invasion. These data suggest an important role for PTTG in tumor cell 
migration and invasion. 
3.2.2 MATERIAL AND METHODS 
Material 
Human embryonic kidney cells (HEK293) and Human umbilical vem 
endothelial cells (HUVEC) were obtained form American Type Culture Collection 
(ATCC, Manassa, VA) and maintained at 3JOC in a humidified atmosphere of 5% 
CO2. HEK293 cells were cultured in DMEM (GIBCO) supplemented with 
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penicillin/streptomycin (100 IU/ml and 1 OO~g/ml) (GIBCO) and 10% FCS (Hyclone, 
Atlanta GA.). HUVEC cells were cultured in ECM medium (Clonetics, US) 
supplemented with Bullet Kit (EGM-2, Clonetics, US). Cells passages were performed 
routinely. The MMP-2 blocking antibody (MMP2BA) was obtained from Chemicon 
USA. Porcine gelatin and clostridium collagenases were from Sigma Chemical Co. 
(St. Louis, MO). DQ Collagen fluroescein conjugate was purchased from Molecular 
Probes (Carlsbad, CA ). 
GE Array Analysis of human extracellular matrix and adhesion molecules 
The expression profile of extracellular matrix & adhesion molecules genes 
were analyzed using the non-radioactive SuperArray GEArray Q series human gene 
array (HS-OI0 SuperArray Bioscience Corp., Frederick, MD). This array membrane is 
composed of 96 extracellular matrix & adhesion molecules genes, a plasmid pUC 18 
negative control, and four housekeeping genes including glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH), cyclophilin A, ribosomal protein L13a, and ~-actin. 
Radioactive [a-32P]dCTP labeled cDNA probes were prepared from 1 ~g of RNA 
from pcDNA3.l and pcDNA-PTTG transfected HEK293 cells each, denatured and 
hybridized to extracellular matrix & adhesion molecules gene-specific cDNA 
fragments spotted on the membranes. After pre-hybridization with GEAhyb 
Hybridization Solution (SuperArray) of denatured salmon sperm DNA (Invitrogen). 
The array membrane was hybridized with denatured cDNA (labeled with a}2P-dCTP) 
probes overnight at 6QoC. After washiu% of the membrane twice with 2 x sse, 1% 
89 
SDS and twice with 0.1 x SSC, 0.5% SDS for 15 min at 55°C, the membranes were 
exposed to x-ray film at _80°C for 24-48 h. The results were analyzed with ScanAlyzer 
and GEArray Analyzer program. The relative expression levels of different genes 
were estimated by comparing its signal intensity with that of internal control ~-actin. 
ELISA for MMP-2 and MMP-9: 
The levels of MMP-2 and MMP-9 in tissue culture supernatants were 
measured using commercially available ELISA kits from BD Biosciences 
(Minneapolis, MN). To measure MMP-2 and MMP-9 in the culture supernatants, 
HEK293 cells were transiently transfected with pcDNA3.1 or pcDNA3.1-PTTG 
cDNA using Fugene6 as the transfectant reagent as described previously (81). After 24 
h oftransfection, the medium was replaced with serum free DMEM medium. Twenty-
four hr later, the medium was collected and concentrated 5-fold (1.0 ml to 200 ).ll) 
using a speedVac system (Savant, Holbrook, NY). The concentration of MMP-2 and 
MMP-9 in a sample was determined by interpolation from a standard curve. All 
measurements were normalized to protein concentration and performed in triplicate. 
Transfection and collection of conditioned media: 
For transient transfection, HEK293 cells were seeded into six well plates 
approximately 24 h prior to transfection,. Cells were transfected in serum-free medium 
using l).lg of plasmid DNA and 3).l1 of transfectin (BioRad) according to the 
manufacture's instructions. After 18 hr of transfection, medium was changed to 
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serum-free medium (DMEM GIBCO) ± MMP-2 blocking antibody 2 ~glml. After 48 
hr, conditioned medium (CM) were collected, centrifuged and stored at -80°C for 
future use. Tissue lysates and stable clones of HEK293 cells transfected with 
pcDNA3.1 or pcDNA-PTTG were generated as describe previously (72). 
Matrix Metalloproteinases-2 (MMP-2) expression and secretion: 
Zymograpby 
Secretion and activity of MMP-2 in conditioned medium collected from cells 
transfected with pcDNA3.1 or pcDNA-PTTG cDNA was used to perform gelatin 
zymography analysis as described by Heussen et.al (159,160). Briefly conditioned 
medium with or without MMP-2 blocking antibody (1: 1 000) was collected and one ml 
of medium was lyophilized and reconstituted with 1 00 ~l of water. Protein was 
determined by the Bradford method (161) and 20 ~g of protein was loaded on 
polyacrlyamide gels containing 0.1 % gelatin Sigma Co. (St. Louis, MO). 
Electrophoresis was performed under non-reducing conditions at 20 rnA for 3 hr at 
room temperature. The gel was washed twice for 30 min each in 2.5% Triton X-I00 to 
remove SDS, incubated in substrate buffer (50 mM Tris-HCl, 5mM CaCh, 0.01% 
NaN3, pH 7.6) for 24 h at 37°C. Gels was stained with 0.5% Coomassie brilliant blue 
G-250 (Pierce Rockford, IL) for 30 min at room temperature, and destained in the 
de staining buffer (30% ethanol, 10% acetic acid, deionized water). The presence of 
metalloproteinases (MMP-2) was indicated by an unstained proteolytic zone of 
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substrate. The gel was scanned using NIH image software, and data are presented as 
fold change relative to control i.e, pcDNA transfected conditioned medium. 
Detection of collagenase activity in conditioned medium and tissue sections. 
Collagenase activity in conditioned medium (CM) 
Twenty III of collagen fluorescent substrate reconstituted in PBS was mixed 
with 80 III of reaction buffer (0.5 M Tris-HCI, 1.5 M NaCl, 50 mM CaCh, 2 mM 
NaN3, pH 7.6) and added to the fluorescent reader plate. Twenty III of conditioned 
medium treated with or without MMP-2 blocking antibody was added to each well. 
Clostridium collagenase, serially diluted was used as a positive control and 100 III of 
reaction buffer was used as a negative control. The plate was incubated at room 
temperature for 1 h. After incubation, the fluorescent intensity of the digested product 
from DQ collagen was measured at excitation 495 nm and emission at 515 nm in the 
fluorescent microplate reader. The fold change was calculated by dividing the mean of 
fluorescence values of conditioned media collected from pcDNA transfected by the 
mean value of fluorescence of conditioned media collected from pcDNA-PTTG 
transfected with or without MMP-2 blocking antibody. 
Collagenase activity in tumor tissue. 
Collagenase activity was determined in tumor tissues extracted from nulnu 
mice as describe previously (72). Briefly, DQ collagen substrate (lmg/ml) was mixed 
with reaction buffer (0.5 M Tris-HCI, 1.5 M NaCl, 50 mM CaCh, 2 mM NaN3, pH 
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7.6) containing 0.8% low melting agarose (Invitrogen) at a ratio of 1: 1 as described by 
Peter et al (162). After melting the agarose mixture at 60°C, the mixture was applied 
on the frozen tissue section on glass slides and allowed to solidify at room 
temperature. Slides were incubated in a humidified chamber with a few drops of 
reaction buffer on each slide for 5-7 days. Assessment of degradation of substrate was 
examined with an Olympus IX50 fluorescent microscope, and photographed with a 
KODAK DC290 digital camera. 
Western blot analysis 
Cells were lysed with lysis buffer (20mM Tris HCI pH7.5, 1 mM EDTA, 0.1% 
Nonidet P-40, 1 mM PMSF, and Il!g/ml each of pepstatin, leupeptin and aprotinin) 
and subjected to SDS-PAGE. The proteins were blotted onto nitrocellulose 
membranes as described previously (124). PTTG protein was detected by using 
polyclonal antiserum (1: 1500) to protein and HRP-conjugated secondary anti-rabbit 
antibody (1 :5000), by the enhanced chemiluminescent substrate (ECL, Amersham). 
Immunohistochemistry analysis 
HEK293 cells were transiently transfected with pcDNA3.l or 
pcDNA3.1 +PTTG vector in chamber slides (Fisher Scientific, Springfield, NJ). After 
24 h of transfection, cells were fixed using 4% freshly prepared paraformaledehyde for 
8 min and then permeabilized by treating with 0.1 % Nonidet P-40 for 5 min. Cells 
were pretreated with 5% normal goat serum for 60 min to block nonspecific binding 
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sites. The tissue was washed with PBS, incubated with anti-PTTG antiserum as 
described (124), and MMP-2 monoclonal antibody(R&D) diluted at (1 :1500). Control 
samples were incubated with preimune serum. After several rinses with PBS buffer, 
the sections were incubated for 45 min with Texas Red conjugated anti-rabbit 
secondary antibody and Texas green conjugated anti-mouse secondary antibody 
(1:100) obtained from Jackson Immuno Research Laboratories (West Grove, PA). 
Cells were analyzed using a fluorescent microscope (Olympus X50). 
Reverse transcription-polymerase chain reaction (RT -peR) 
Total RNA was isolated from transfected HEK293 cells in log phase and tumor 
tissues using Trizol reagent (Gibco-BRL) as described previously (25). In brief, 
samples were homogenized in 5 ml of Trizol reagent, after vortexing for 2 min, 1 ml 
of homogenate was distributed in five 1.5 ml Eppendroff tubes and kept at room 
temperature for 5 min, 1/5 volume of chloroform was added to each sample followed 
by vigorous mixing and incubation for 2-3 min. The aqueous phase was removed after 
centrifugation at 15,000 rpm and precipitated with isopropanol. The RNA was washed 
once with 70% ethanol. After air-drying, the RNA was resuspended in RNase free 
water. Total RNA concentration was determined spectrophotometrically at 260 nm. 
Using iScript RT-PCR kit (Bio-Rad), first strand cDNA was synthesized and 
subsequently used for PCR amplification using the specific primers for MMP-2, MTI-
MMP, PTTG, and GAPDH (72,163) (Table 3) using Taq polymerase (Takra Co.). 
PCR conditions were 95°C for 5 min, 95°C for 1 min, 54°C for 30 sec and noc for 30 
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sec for 30 cycles with a final extension for 5 min at 72°C. Ten ~l PCR product from 
each sample was subjected to electrophoresis on a 1.5% agarose gel. 
In-vitro invasion assay 
PTTG stably transfected HEK293 cells were used for invasion and migration 
assays. Boyden chamber matrigel coated wells (BD BioCoat Invasion System) were 
used according to the manufactuer's instructions. HEK293 cells were dislodged non-
enzymatically (TryplE, Invitrogen, IL) and resuspended in DMEM serum-free culture 
medium, with or without MMP-2 blocking antibody at 2xl05 cells/ml and 0.25 ml of 
cell suspension was transferred to the top chamber. Medium with 2% FBS was added 
to the lower chamber. The plate was incubated at 37°C, 5% C02 atmosphere for 22 h. 
Non-migrated cells in the upper chamber were removed with clean cotton swab, and 
migrated cells on the bottom of the membrane were stained with Eosin and Gimsa 
stain. The migrated cells were counted and invasion index was calculated by dividing 
the percent of cells that migrated through the matrigel by the percent of cells that 
moved through the pores of uncoated wells. The effect of secreted MMP-2 on 
HUVEC cells invasion and migration was also performed using conditioned media in 
the lower chambers of Boyden chamber wells. 
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Wound migration assay. 
The wound migration assay was performed as described by Cheresh et al (164) 
with slight modifications. HUVEC cells were grown in 35mm culture dishes to 80% 
confluence. A wound was formed using a 200 III pipette tip to clear the cell 
monolayer, and the boundary of the wound was marked. Cells were then washed three 
times with PBS. The conditioned medium (CM) was applied in different combinations 
with and without the MMP-2 blocking antibody. Mouse IgG (Sigma) was used as a 
control. Cells were incubated for 18-20 h at 37°C, under a 5% C02 atmosphere. After 
incubation, cells were fixed with absolute methanol, stained with diluted (1: 10) 
Giemsa stain (Sigma Chemical Co., St. Louis MO), and photographed. Cell migration 
was measured by counting the number of cells that migrated into the clear space using 
an Olympus X-50 microscope at 100 X fitted with an ocular grid. The values 
represented are the mean of four different random fields. The fold change was 
determined by dividing the mean number of cells that moved from the wound edge in 
the experimental cultures by those that moved from the wound edge in the control 
cultures. HEK293 cells constitutively expressing PTTG were grown in 35 mm tissue 
culture dishes to 80% confluence. A wound was formed with a 200 ul pipette tip. Cells 
were washed thrice with IX PBS. Five ml of DMEM serum-free medium was added 
to the dishes with or with MMP-2 blocking antibody (MMP2BA). After 24 hr of 
incubation, cells were fixed with methanol, stained with 1: 1 0 diluted Giemsa stain, 
and photographed as described earlier. 
98 
Tubule formation assay in 3D matrigel matrix: 
Forty-eight well plates were coated with 20 Ilg/ml of matrigel (GF-reduce BD 
Bedford MA). HUVEC cells (2x103 cell/ml) were plated on the matrigel matrix with 
conditioned medium (CM) with or with out MMP-2 blocking antibody for 24 h. After 
4 h 100 III of matrigel-CM (matrigel + condition medium mixture 1:2 ratio) was 
overlaid on cells. Cells were allowed to differentiate into tubule according to Lewis et 
al (165). After 3 days, tubule formations were assessed by fixing the cells with 
methanol for 15 min, followed by rinsing with PBS. Three random fields of view in 
three replicate wells for each test condition was visualized under high power Olympus 
IX50 (X400). Color images were captured using Kodak DC290 digital camera linked 
to a computer with Adobe Photoshop 7 software. Quantification of tubule formation 
was carried out by counting the number of tubule branches and the total area covered 
by tubules in each field of view using image analysis software Photoshop version 7. A 
numerical value was assigned to each pattern according to the network of tubule 
formation. A numerical value of 0-1 is given when the cells are well separated, 2-3 
when cells begin to migrate and align to form tubes, and 4-5 when capillary tubes or 
closed polygons begin to form. 
Luciferase Assay: 
A human MMP-2 promoter (1959 bp of the sequence upstream from the 
transcription start site) cloned into luciferase reporter construct (pGL-MMP2) was 
obtained from Dr. Etty Beneveniste, University of Alabama at Birmingham, AL 
(Figure 18) (166). Five hundred ng of the MMP-2 promoter construct or pGL2 
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construct was co-transfected with 500 ng pcDNA-PTTG and 100 ng of the renilla 
construct into 3 x 106 HEK293 cells using Transfectin (Bio-Rad). After transfection, 
cells were allowed to recover for 18 h and then cultured in 10% FCS/DMEM for 24 h. 
Cells were washed in PBS and lysed with 500 ).11 of IX lysis buffer (Promega); 
luciferase activity was then determined in triplicate as described by the manufacturer. 
The luciferase activity of each sample was normalized to renilla activity. The fold 
change in luciferase activity was calculated by dividing the relative luciferase activity 
ofPTTG-pGL-MMP2 promoter activity by PTTG-pGL luciferase relative activity. 
Statistical Analysis: 
Statistical comparison of data sets was carried out by the Student's t test 
(single comparison) or by one-way ANOV A (multiple comparison) when data sets 
complied with the condition of normality and equal variance. Under other conditions, 
comparisons were carried out by nonparametric analysis using the Mann-Whitney 
rank-sum test (single comparisons) or the Kruskal-Wallis one-way ANOV A on ranks 
(multiple comparisons). The Bonferroni methods (parametric test) or the Dunett 
methods (nonparametric test) were used to identify data sets that differed from the 
control data in multiple comparisons. Probability of p <0.05 determined from the two-
sided test were considered significant. The statistical analysis was carried out by using 
SPSS 10.0 software. 
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Figure 18: Key regulatory elements in 1959 bp upstream of transcription start site of 
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RESULTS 
PTTG increases the expression and activity of MMP-2 in-vitro 
Gelatinase A (MMP-2) was reported to correlate with invasive and metastatic 
behavior of malignant tumors. Induction of MMP-2 protein had been implicated in 
various diseases including tumor progression and metastases. We therefore measured 
the expression and secretion of MMP-2 in HEK293 cells transiently transfected with 
pcDNA3.1 and pcDNA3.1-PTTG·cDNA using The GE array for human extracellular 
matrix and adhesion molecules and ELISA. As shown in (Figure 19 A and B), MMP-
2 expression was ~8 fold increased in the cells transfected with pcDNA-PTTG as 
compared to cell transfected with pcDNA vector alone. Also, there was ~5 fold 
increases in the MMP-2 secretion in pcDNA-PTTG transfected cells as compared to 
pcDNA transfected cells. As shown in (Figure 19 C and D), MMP-2 mRNA levels of 
MMP-2 protein in pcDNA3.1-PTTG transfected cells were increased by 22 fold 
(p<O.05) compared to HEK293 cells transfected with vector-alone. Co-transfection of 
HEK293 cells with pGL-MMP-2-Luc reporter gene and with pcDNA-PTTG resulted 
in luciferase activity increased by 13 fold (p<O.05) relative to control pGL2 vector 
(Figure 20). Measurement of the functional activity ofMMP-2 by zymography (Figure 
21) and fluorescent collagenase substrate degradation revealed more than two-fold 
increased in MMP-2 activation in cells transfected with PTTG cDNA compared to 
cells transfected with vector alone (Figure 22). These data suggest that PTTG 
increases MMP-2 expression as well as its activity, both of which may be required for 
the tumor angiogenesis and invasive phenotype to degrade ECM to pave the way for 
metastases. 
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Figure 19: A: Selected data from GE Array for human extracellular matrix and 
adhesion molecules are increased by more than two fold in HEK293 cells transfected 
with pcDNA-PTTG vs pcDNA3.1. B: Measurement of MMP-2 and MMP-9 in 
conditioned medium using ELISA, MMP-2 was approximately increased by 5-fold in 
HEK293 cells transfected with pcDNA-PTTG compared to pcDNA transfected cells. 
C: Semi quantitative RT-PCR for MMP-2 and GAPDH. D: Graphical representation 
of the data shown in MMP-2 expression was increased by -22 fold in HEK293 cells 
transfected with pcDNA-PTTG compared to pcDNA3.1 transfected cells. (** 
p<0.05). 
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Figure 19 A and B 
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Figure 20: MMP-2 promoter activation. MMP-2 promoter activity was increased by 
~ 13 fold in cells transfected with pcDNA-PTTG as compared to pcDNA transfected 
cells. Error bars represent mean ± SEM (n = 3). (** p<0.05) 
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Figure 20 











Figure 21: A: Gelatin zymography. Activity of MMP-2 was increased in conditioned 
medium from HEK293 cells transfected with pcDNA-PTTG compared to cells 
transfected with pcDNA plasmid. B: Densometric analysis of zymography showing 
increase in inactive and active forms of MMP-2 in conditioned medium from HEK293 
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Figure 22: Direct Quenching (DQ) Fluorescein conjugate collagenease analysis. 
Activity of collagenase was approximately 2.5 fold higher in conditioned medium 
from HEK293 cells transfected with pcDNA-PTTG as compared to cells transfected 
with pcDNA plasmid. Addition of MMP-2 blocking antibody (MMP2BA) completely 
blocks the collagenase activity. Data represent the mean ± SEM of experiments 
performed in triplicate. (* pO.OS) 
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Figure 22 
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PTTG increases invasion and migration in-vitro. 
To determine the role of PTTG on invasion and migration through MMP-2, we 
used stably transfected HEK293 cells seeded on Boyden chamber wells. HEK293 
stably transfected with PTTG cDNA cells showed higher invasive index compared to 
HEK293 stably transfected with vector alone (Figure 23). We also observed a 
complete inhibition of invasion and migration of cells in medium containing MMP-2 
(2~g/ml) blocking antibody (MMP2-Ab) as compare to conditioned medium from 
pcDNA-PTTG transfected cells, and no effect on invasion with the addition of mouse 
IgG (2~g/ml) as control. 
Similar results were obtained using HUVEC cells. Increased invasion and 
migration was observed in the conditioned medium from HEK293 transfected with 
PTTG cDNA as compared to conditioned medium from vector transfected cells. 
Complete inhibition of migration and invasion was observed when MMP-2 (2~g/ml) 
blocking antibody was used as compared to control or without antibody. 
PTTG increases the migration of HUVEC Cells in-vitro. 
A wound migration assay was performed in 35mm culture plates seeded with 
HUVEC, and migration was quantified by counting the number of cells that migrated 
into the non-wounded area using a microscope eyepiece marked 
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Figure 23: PTTG increased the invasion of HUVEC and HEK293 stably transfected 
cells. A Matrigel coated Boyden invasion chamber assay was performed to evaluated 
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grid (1 mm2 ). HUVEC cultures were incubated for 48 h in conditioned media from 
HEK293 cells transfected with pcDNA3.l or pcDNA-PTTG. There was a 95% 
increase in cell migration into non-wound area when conditioned medium from 
pcDNA3 .1-PTTG compared to medium from cells transfected with vector alone 
(Figure 24). Specific MMP-2 blocking antibody suppressed migration by 87% into the 
wounded area as compared to conditioned medium from pcDNA-PTTG, but there was 
no effect on migration with rabbit/mouse IgG (data not shown). 
PTTG increases tubule formation and growth in 3D matrigel matrix. 
MMP-2 plays an important role in the proteolysis of ECM that allows 
endothelial cells to migrate toward the angiogenic stimuli and form the blood vessels 
that nurture tumor development. A HUVEC cell in three dimensional matrigel matrix 
was mixed with conditioned medium from HEK293 transfected cells with pcDNA or 
pcDNA-PTTG with or without MMP-2 blocking antibody. As shown in (Figure 25) 
the tubule formation was enhanced in CM from pcDNA3.1-PTTG as compared to 
vector alone. Treatment with MMP-2 blocking antibody completely abolished tubule 
formation, suggesting an important role ofMMP-2 in angiogenesis. On the other hand, 
when stable transfected HEK293 cells were grown on a matrigel matrix, cells which 
were transfected with vector alone did not grow and remained spherical after 48 hrs 
(Figure 26), whereas cells transfected with pcDNA-PTTG spread out and started 
116 
Figure 24: Conditioned medium from PTTG transfected HEK293 cells increased the 
migration of HUVE cells as compared to pcDNA transfected HEK293 cells. 
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Figure 24 
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Figure 25: Tubule formation assay: HUVEC cells were grown in matrigel matrix 
mixed with conditioned medium collected from pcDNA-PTTG or pcDNA3.l 
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growing within 24 h. On the other hand, inclusion of MMP-2 blocking antibodies, 
completely blocked the growth of these cells. These data suggest a role for MMP-2 in 
proliferation and growth of cells. 
PTTG increases the expression of alpha-5, alpha-V, beta-l and beta-3 integrins. 
Integrins are a diverse family of glycoproteins that form hetrodimer receptors for 
ECM molecules. The family can form at least 25 distinct pairs of 18 a-subunit and 8 
~-subunits, with each other specific for a unique set of ligands. Integrin aV~3 binds a 
wide range of ECM molecules including fibronectin, fibrogen, vitronectin and MMP, 
and proteolyse collagen and laminin, whereas a5~1 selectively binds to fibronectin 
(167). Numerous studies have documented marked differences in surface expression 
and disregulation of integrins in malignant tumors compared with pre-neoplastic 
tumor of the same types (168). Integrin a5~3 is strongly expressed at the invasive front 
of malignant melanoma cells and angiogenic blood vessels (169), and expression of av 
and ~3 integrin increases the metastatic potential of various tumor cell lines (170). As 
shown in (hgurc 27) the mRNA levels of alpha-5, alpha-V, beta-l and beta-3 are 
significantly increased in HEK293 cells transfected with pcDNA-PTTG as compared 
to pcDNA3.l 
PTTG increases the expression and secretion of MMP-2 in-vivo. 
Analysis of MMP-2 expression, secretion, and activity in tumors excised from 
nude mice overexpressing PTTG confirmed the higher expression of MMP-2 mRNA 
121 
(Figure 28) measured by RT/PCR, activity measured by zymography, and DQ 
fluorescent substrate activity. 
3.2.5 DISSCUSSION: 
Pituitary tumor transforming gene (PTTG) is a potent oncogene expressed at 
high levels in almost all malignant tumor analyzed to date. Its oncogeneic potential 
was demonstrated by its over-expression in mouse fibroblast NIH3T3 and HEK293 
cells, which showed increased proliferation, colony formation on soft agar and tumor 
formation in nude mice (24,27,72). Expression ofPTTG has been reported to correlate 
with highly aggressive and metastastic tumors (33,71), and to regulate the expression 
of many growth and angiogenic factors such as bFGF, VEGF and IL-8 (72). However, 
the mechanism by which this aggressive behavior is regulated remains unclear. 
Metalloproteinases are central to the ability of cancer cells by regulating the 
extracellular matrix (ECM) around them. They degrade the matrix, and make way for 
the tumor cells to migrate and metastasize to distance sites. It is well recognized that 
MMPs are also involved in the expression and activation of various chemokines, 
growth factors and their receptors (171). Multiple MMPs are involved in the 
degradation of the surrounding matrix, but MMP-2 has been at the forefront in tumor 
invasion, angiogenesis, and formation of metastases. Tumor and stromal cells express 
high levels of MMP-2, which allows the cells to invade and metastasize. However 
cellular mechanism by which MMP-2 is regulated is not fully understanded. To 
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Figure 26: Three dimensional growth assay. HEK293 cells were grown in matrigel 
with or without MMP-2 blocking antibody mixed with conditioned media from 
pcDNA-PTTG or pcDNA3.l transfected HEK293 cells. 
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Figure 26 
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Figure 27: Semi quantitative RT-PCR for Integrins and GAPDH. Expression of beta-
1, beta-3, alpha-5, and alpha-V was increased in HEK293 transfected with pcDNA-
PTTG cells as compared to pcDNA3.1 transfected cells. Densometric analysis of gel 


















Figure 28: Expression of PTTG and MMP-2 in tumor excised from nude mice. A: 
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investigate the interrelation between PTTG and MMP-2 in anglOgemc and 
InVaSIVeness of tumor cells, we selected HEK293 cells. Stable overexpression of 
PTTG in HEK239 increased the expression and secretion of MMP-2, which in tum 
increased invasion, migration, and tubule formation of HUVEC cells treated with 
conditioned medium. Treatment with specific MMP-2 blocking antibody inhibited 
migration, invasion, and tubule formation of HUVEC cells, suggesting that MMP-2 is 
crucial in migration, invasion, and angiogenesis. Many studies have implicated MMP-
2 in tumor angiogenesis and metastases (172-174). Itoh et al reported a significant 
reduction in angiogenic activity and subsequent tumor progression in MMP-2 
deficient mice (141). Others have shown that MMP-2 is required for tumor 
angiogenesis and metastases (158,175). As cancer cells become metastatic and 
endothelial become angiogenic, they develop altered affinity for their extracellular 
matrix. Some of these changes are mediated by alteration in the expression of cell-
surface molecules known as integrins. Integrins are involved in regulating the 
activities of proteolytic enzymes that degrade the basement membrane, the initial 
barrier to surrounding tissue, by directly mediating adhesion to ECM, and also by 
regulating intracellular signaling pathways that control cytoskeleton organization. As 
PTTG is involved in regulation of cell cytoskeleton (45) these changes could occur 
through the expression of different integrins on the cell surface, as we have showed 
that integrin av, as, ~l and ~3 expression is measured by overexpression of PTTG in 
HEK293 cells. Integrin av and ~l have been impicated in the regulation of 
metalloproteinases MMP-2 and MTI-MMP with whom it forms a complex in highly 
invasive phenotypes of metastatic tumors (176,177). In previous studies, we (72) 
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showed that PTTG stimulates the expression of bFGF, VEGF and IL-8, which may 
induce the expression of MMP-2 (178). Overexpression of PTTG in HEK293 cells 
may have autocrine effects on the expression of MMP-2 initiated by growth factors. 
However, the studies done by Hyuga et al (179) showed autocrine factors were not 
responsible for the upregulation of MMP-2 in highly metastastic cell line. Tumors 
excised from nude mice also displayed higher expression and collagenase activity 
when compared to normal organs from the same animals, except in the liver and 
kidney which express MMP-2 for their normal function (180,181). 
In summary, our results provide evidence that PTTG contributes to cell 
migration, invasion and angiogenesis by induced of MMP-2 expression and secretion. 
Further, we showed that tumors from nude mice have high expression and secretion of 
MMP-2 which contributed to high gelatinolytic activity. However, due to the 
expression of other contributing growth factors we are unable to show autocrine effect 
on MMP-2 expression and secretion. Further studies are needed to separate the 
autocrine effect of growth factors on MMP-2 expression. 
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Chapter IV 
Regulation of Matrix Metalloproteinase-2 (MMP-2) in human tumor cells lacking 
Pituitary Tumor Transforming Gene (PTTG -/-). 
INTRODUCTION 
Tumorigenesis is a multistep process. Abnormal gene expression is associated 
with several characteristics that differentiate tumor cells from normal cells, including 
alterations in cell differentiation, invasion, migration, metastasis, angiogenesis and 
apoptosis. Over-expression of human pituitary tumor transforming gene (PTTG) in 
mouse fibroblast NIH3T3 cells and human embryonic kidney (HEK239) cells results 
in increased cell proliferation, induction of the cell foci formation and promotion of 
tumor formation in nude mice (24,26,27,72). These finding suggest that PTTG is a 
potent human oncogene. Data from our laboratory and others suggested that PTTG 
may act through bFGF, VEGF, IL-8 and MMP-2 to achieve cellular transformation 
leading to tumorigenesis. 
Local invasive growth is a key event of primary malignant tumors. A 
correlation between the expression levels of PTTG and invasiveness and degree of 
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malignancy in pituitary, colorectal and thyroid tumor has been demonstrated 
(33,35,36). However, specific mechanisms facilitating the invasive behavior of cells 
expressing PTTG remains unclear. Interaction between cancer cells and surrounding 
normal cells, involving extra-cellular matrix (ECM) are thought to be the key to tumor 
cell invasion (182,183). To invade and metastasize into the surrounding normal 
tissues, tumor cells must degrade multiple elements of the ECM, including fibronectin, 
laminin, and type IV collagen (183). Several metalloproteinases (MMPs) are required 
for the degradation of the ECM and these are classified according to their substrate 
specificity. Gelatinases (MMP-2 and MMP-9) are the most common MMPs found in 
tumors, and elevated levels of these enzyme have been reported in various cancers 
(183). MMP-2 is also known to be involved in tumor angiogenesis through 
degradation of extracellular matrix which can result in tumor cell as well as 
endothelial cell migration due to loss of cell-matrix and cell-cell contacts (145). MMP-
2 is also capable of releasing growth factors from ECM, cleaving growth factor 
receptors and activating growth factors excreted as pre-pro-enzymes, such as 
transforming growth factors (TGFu, TGFP), macrophage-colony stimulating factor 
(M-CSF), insulin like growth factor (IGF) and fibroblast growth factor receptor 
(FGFR) (146-148). 
As discussed in the chapter III, PTTG regulates the expression and secretion of 
MMP-2 in HEK293 cells. Recent data from our laboratory Kakar et al; (184) and 
others (70,86-88) showed that attenuating PTTG expression using siRNA, antisense 
oligos or adenovirus mediated transfer of siRNA against PTTG, inhibit tumor growth 
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of ovarian, lung and hepatoma cancer cell lines in vitro and in vivo. None of these 
studies examined the metastastic or invasive properties of these tumors. The aim of 
this study is to utilize cancer cells genetically lacking PTTG gene to determine its 
effect on tumor invasiveness and determine the role ofMMP-2 in such regulation. We 
hypothesized that deletion of PTTG will reverses the invasive phenotype by 
decreasing MMP-2 expression and secretion. To support our hypothesis we used 
human colorectal tumor cell line HCT116 lacking PTTG (PTTG -1-), and wild type 
HCT116 (PTTG +1+) cells as control. These cell lines were a generous gift from Dr. 
Vogelstein (John Hopkins Oncology Center and Howard Hughes Medical Institute. 
Baltimore. Maryland) (89). 
4.2 MATERIAL AND METHODS: 
Cell cultures 
Human colorectal cancer cells lines were obtained from Dr. Bret Vogelstein 
(The John Hopkins Oncology Center and Howard Hughes Medical Institute. Baltimore 
Maryland) (89) and propagated as described elsewhere (185,186). 
Western Blot: 
Cells growing in log phase were lysed in chilled lysis buffer [50 mM Tris-HCl 
(pH 7.5),150 mM NaCl, 1% NP-40, 1 mM Na3V04, and 1 mM NaF] supplemented 
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with Complete Mini Protease Inhibitor tablets (Roche Molecular Biochemicals, 
Indianapolis, IN). Equal amounts of protein extracts (40 ug) were resolved on 12% 
SDS-PAGE gel, and transferred to a nitrocellulose membrane (Amersham, 
Piscataway, NJ). Blots were probed with PTTG antiserum at a dilution of 1: 1 ,500 as 
described previously (124). Immunoreactive proteins were visualized using the 
Enhanced Chemiluminescent Detection System (Amersham) according to the 
instructions provided by the supplier. 
Reverse Transcription Polymerase Chain Reaction (RT -PCR): 
Total RNA from cells was purified using Trizol reagent (Invitrogen, Carlsbad, 
CA) following the manufacturer's instructions. The RNA pellets were resuspended in 
RNase-free water, and contaminating DNA was removed from the preparations with 
DNase!. The yield of total RNA was measured using a spectrophotometer, and the 
quality was assessed by electrophoresis through a 1 % agarose gel. First strand cDNA 
was synthesized using the iScript™ cDNA synthesis kit (BioRad, Hercules, CA). PCR 
primers were designed, based on the human PTTG, MMP-2 and GAPDH cDNA 
sequences. The PCR conditions for each gene are listed in Table 1 & 2. GAPDH 
amplification was used as an internal control. Ten III from a total of 50111 PCR reaction 
mix was applied to a 2% agarose gel. After electrophoresis the gel was stained with 
ethidium bromide to visualize PCR products. The densitometric values for the PCR-




Secretion and activity of MMP-2 in conditioned medium collected from cells was used 
to perform gelatin zymography analysis as described by Heussen et al (159,160). 
Briefly conditioned medium was collected and one ml of medium was lyophilized and 
reconstituted to 100 I.d with water. Protein was determined by Bradford method (161) 
and 20 ~g of protein from each sample was loaded on polyacrlyamide gel containing 
0.1 % gelatin Sigma Co. (St. Louis, MO). Electrophoresis was performed under non-
reducing conditions at 20 rnA for 3 hr at room temperature. The gel was washed twice 
for 30 min each in 2.5% Triton X-IOO to remove SDS, incubated in substrate buffer 
(50 mM Tris-HCI, 5mM CaCh, 0.01 % NaN3, pH 7.6) for 24 h at 37°C. The gel was 
stained with 0.5% Coomassie brilliant blue G-250 (Pierce Rockford, IL) for 30 min at 
room temperature, and de stained in the de staining buffer (30% ethanol, 10% acetic 
acid, deionized water). The presence of metalloproteinases (MMP-2) was indicated by 
an unstained proteolytic zone of substrate. The gel was scanned using NIH image 
software, and data are presented as fold change relative to control i.e, HCTl16 WT-
conditioned medium. 
Detection of collagenase activity in conditioned medium and tissue sections. 
Collagenase activity in conditioned medium (CM) 
Twenty microliters of collagen fluorescent substrate reconstituted in PBS was 
mixed with 80 ~l of reaction buffer (0.5 M Tris-HCL, 1.5 M NaCI, 50 mM CaCh, 2 
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mM NaN3, pH 7.6) and added to the fluorescent reader plate. Twenty III of 
conditioned medium was added to each well. Clostridium collagenase, serially ten fold 
serially diluted used as a positive control and 100 III of reaction buffer was a negative 
control. The plate was incubated at room temperature for 1 h. After incubation, the 
fluorescent intensity of the digested product from DQ collagen was measured by 
excitation at 495 nm and emission at 515 nm in the fluorescent microplate reader. The 
fold change in activity was calculated by dividing the mean of fluorescence values of 
conditioned media collected from HCTl16 WT by the mean value of fluorescence of 
conditioned media collected from HCTl16 Null (PTTG-I-) cells. 
Luciferase Assay: 
A human MMP-2 promoter (1959 bp upstream from transcription start site) 
luciferase reporter construct (pGL-MMP2) was obtained from by Dr. Etty 
Beneveniste, University of Alabama at Birmingham, AL (166). Five hundred ng of 
the MMP-2 promoter construct or pGL2 was co-transfected with 100 ng of a renilla 
construct into 3 x 106 HCT116 WT and HCT116 Null (PTTG-I-) cells using 
Transfectin (Bio-Rad). After transfection, cells were allowed to recover for 18 hand 
then cultured in 10% FCS/DMEM for 24 h. Cells were washed in PBS and lysed with 
500 III of IX lysis buffer (Promega). Luciferase activity was determined in triplicate 
as described by manufacturer. The luciferase activity of each sample was normalized 
to renilla activity to determine the relative luciferase activity (RLA). The fold change 
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in RLA was calculated by dividing the relative luciferase activity of HCTl16 WT-
pGL-MMP2 promoter activity by HCTl16 Null-pGL-MMP-2Iuciferase activity. 
Migration Assay: 
HCT116 WT and HCT116 Null (PTTG-/-) cells were cultured in McCoy's 
medium containing 100 mllL FBS and 10 gIL penicillin-streptomycin in a 50 mllL 
CO2 incubator at 3TC. Assessment of HCTl16 migration was performed as recently 
described (187) with minor modifications. HCT116 cells were dispersed into 
homogeneous single cell suspensions after trypsinization. These cells were extensively 
washed with McCoy medium containing 1 giL fatty acid-free BSA and resuspended in 
the same medium. HCTl16 cells (105) were dispersed onto the upper chamber of 
transwell compartment with an 8 ~m pore size filter (QCM Cell Migration Assay, 
Chemicon. USA). The cells were allowed to adhere for 1 h at 3TC. The medium in 
the lower chamber was removed and replaced by growth medium alone. Migration 
was allowed to proceed for 24 h at 3TC. The remaining cells attached to the upper 
surface of the filters were carefully removed with cotton swabs. Migrated cells were 
stained with crystal violet and examined by light microscopy and photographed. The 
number of migrated cells was quntitated by dissolving stained cells in 10% acetic acid 
and transfering a 1 00 ~l of dye/solute mixture to a 96 well plate for colorimetric 




HCT116 WT and HCT116 Null (PTTG-I-) cells were cultured in McCoy 
medium containing 100 mllL FBS and 10 giL penicillin-streptomycin in a 50 mIlL 
CO2 incubator at 3TC. Assessment of HCT116 migration was performed as recently 
described above (187-189). 
Percent Invasion: 
Percent invasion was calculated by dividing mean of cell invaded through 
matrigel insert membrane by mean of cells migrating through control insert membrane 
and multiplied by 100. 
Statistical Analysis: 
Statistical comparison of data sets was carried out by the Student's t test, and 
by one-way ANOV A for multiple sets using SPSS v 10. 
4.3 RESULTS: 
Loss of PTTG expression in HCT116 (PTTG -1-) correlates with the expression 
ofMMP-2. 
Over-expression of MMP-2 correlates to an invasive phenotype in several 
cancer types and is often predictive of poor survival (140). MMP-2 null mice display 
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lower lung colonization following intravenous administration of cancer cells and 
reduced tumor angiogenesis resulting in reduced tumor growth (141). PTTG regulates 
the MMP-2 expression in the HEK293 cell line, which increases the invasive behavior 
of these cells. To determine the functional effect of PTTG on MMP-2 regulation, 
colorectal cancer cell lines lacking PTTG gene HCT116 (PTTG -1-) and its control 
HCTl16 wild type (PTTG +1+) were used. 
To test the validity of HCT116 (PTTG +1+ and -1-) cell lines as a model 
system, western blot analysis for PTTG was carried out. As shown in (Figure 29), 
expression of PTTG protein in HCTl116 (PTTG -1-) was undetectable, whereas 
HCT116 (PTTG +1+) cells showed high levels of PTTG protein. Further, to 
demonstrate an effect of PTTG on MMP-2 gene transcription, MMP-2 promoter 
activity was measured in HCT116 (PTTG +1+) and HCTl16 (PTTG -1-) cell lines. 
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Figure 29: Western blot analysis of HCT116 wild type and HCT116 (PTTG -1-) cells 








A 1659 bp DNA fragment containing human MMP-2 gene promoter cloned into the 
pGL3 (Promega) vector was co-transfected with renilla vector. After 24 h growth 
medium was changed to serum-free medium. 24 h after the change in medium, the 
cells were lysed and assayed for luciferase activity as described previously (80). As 
shown in (Figure 30) MMP-2 promoter activation was increased by ~8 fold higher 
(p<0.05) in HCT116 (PTTG +1+) compared to the HCTl16 (PTTG -1-) cell line. 
Similar results were obtained by the semi-quantitative reverse transcription (RT-PCR) 
analysis of messenger RNA of PTTG and MMP-2. As shown in (Figure 3]), the level 
of PTTG mRNA was higher in wild type HCT116 cells but undetectable in HCT116 
(PTTG -1-) cell line. Similarly, the mRNA level of MMP-2 was higher in HCT116 
(PTTG +1+) compared to HCTl16 (PTTG -1-) cells. As described in chapter III, over-
expression of PTTG increases the expression of MMP-2 in HEK293 cells. To confirm 
our results of MMP-2 we measured MMP-2 secretion and activity in HCT116 cells. 
DQ-collagenase and zymography assays. As shown in (Figure 32), there was 
substantially less secretion of MMP-2 by the HCT116 (PTTG -1-) cell lines as 
compared to HCT116 (PTTG +1+) cell line. Furthermore, the collagenolytic activity of 
MMP-2 was reduced by 30% in medium from HCT116 (PTTG -1-) as compared to 
HCT116 (PTTG +1+) cells. 
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Figure 30: Luciferase assay ofMMP-2 promoter transfected in HCTl16 wild type and 
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Figure 31: Semi-quantitative RT-PCR for PTTG, MMP-2 and GAPDH in HCT116 
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Figure 32: Zymography and Collagenase assay of conditioned media collected from 
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Decrease in MMP-2 expression reduces the invasive phenotype of HCT116 
(PTTG -1-) cell line. 
A relationship between PTTG expression and metastasis has been reported 
(33,68) in limited studies in colorectal and pituitary adenocarcinomas. As mentioned 
earlier, MMP-2 is thought to have a prominent role in tumor cell invasion and is 
increased by PTTG. We next tested ifPTTG stimulated the expression ofMMP-2, the 
invasive behavior ofHCTl16 (PTTG +1+) and HCTl16 (PTTG -1-) cells. The Boyden 
chamber matrigel invasion assay were used to measure the invasive index of both cell 
lines. As shown in (Figure 33 A) there was a significant decrease in both invasion and 
migration of HCT116 (PTTG -1-) cells as compared to HCT116 wild type. There was 
also a ~39 % reduction in invasion of HCT116 (PTTG -1-) compared to HCT116 
(PTTG +1+) (Figure 33 B). These results suggest that PTTG modulates the expression 
ofMMP-2 in mediating its tumorigenic function. 
4.4 DISCUSSION 
In this chapter it is shown that PTTG plays an important role in regulating the 
expression of MMP-2. Deletion of the PTTG gene from the HCT116 cell line is 
associated with a reduction of MMP-2 expression an~ decreased invasive capacity of 
this cancer cell line. These finding are consistent 
149 
Figure 33: Invasion and migration assay using HCTl16 wild type and HCTl16 (PTTG 
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with the previous results from our group using siRNA against PTTG (184) and others 
using PTTG full length anti-sense mRNA (88), or oligonucleotides against PTTG 
mRNA (190), reduced colony formation on soft agar, and suppression of tumor 
development in nude mice. PTTG is over-expressed in most types of cancer and plays 
an important role m tumor . . angIOgenesls, metastasis and growth 
(24,25,33,71,72,124,151). Over-expression of PTTG has been shown to induce 
cellular transformation and to promote tumor development in nude mice (72). MMP-2 
plays an important role in local invasion, angiogenesis and growth. A correlation 
between the levels of expression of PTTG with increased tumor invasiveness and 
degree of malignancy in pituitary and colorectal tumors have been demonstrated 
(33,68). Melmed et al (85) showed that when the PTTG gene is ablated animals 
exhibited impaired proliferation of pancreatic p-cells and developed type I diabetes 
during late adulthood, suggesting the importance of PTTG in p-cell proliferation. 
These results are in agreement with Perez et al (191) showing that MMP-2 is required 
for pancreatic islet cell formation (191), and other studies of diabetes and p-cell 
dysfunction where MMP-2 expression is impaired (192). These results suggest that 
PTTG null animals have impaired pancreatic p-cell proliferation and development of 
diabetes may be due to impaired MMP-2 expression. 
MMP-2 activity was still observed in PTTG -/- cells line, suggesting that 
PTTG is not the only factor which can lead to the regulation ofMMP-2 (193-196). On" 
the other hand, PTTG ablation in HCT116 may change the phenotypic characteristic 
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of the cells during positive selection, and other genetic or biochemical alterations 
which might have occurred that lead to cell survival cells without PTTG. 
In conclusion, PTTG expression correlates with the expression of MMP-2 in 
HCT116 cell lines. Depletion of PTTG from HCT116 (PTTG -1-) decreased the 
transcription of MMP-2, which in-tum decreased the expression, secretion, and 
activity of MMP-2. These together effect cell migration and invasion characteristics of 
HCTl16 cells. The data suggest that PTTG is a potent oncogene that may act through 
bFGF, VEGF, IL-8 and MMP-2 to induce transformation, cell proliferation, 
angiogenesis, invasion, and metastasis. MMP-2 is crucial in all steps of tumorigenesis; 
blocking MMP-2 activity can inhibit the multistep process of tumorigenesis. 
153 
Chapter V 
CONCLUSIONS AND DISCUSSION 
Pituitary tumor transforming gene (PTTG) is a relatively recently isolated 
proto-oncogene that has been identified as a mammalian securin protein implicated in 
chromatid separation during cell division (45). Expression of PTTG is cell cyc1e-
dependent both at the protein and mRNA levels (45,47,66). By virtue of mammalian 
securing activities, PTTG over-expression inhibits of chromatid separation which may 
lead to genetic instability, aneuploidy and thereby tumorigenesis (45) The oncogeneic 
function of PTTG was established by over-expressing the protein in mouse fibroblast 
cell line (NIH3T3) and assessing its ability to induce cellular transformation and 
tumor formation in the nude mice (24,27). Expression of PTTG in NIH3T3 cells 
increaseds bFGF and VEGF expression thereby leading to tumorigenesis and 
angiogenesis in vitro and in vivo (35,90). bFGF and VEGF are major activating factors 
in mitogenesis and angiogenesis (90,91). Thus, PTTG may playa role in tumor 
progression and angiogenesis. 
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There are numerous instances in which overexpreSSlOn of oncogenes induce 
transformation rodent cell lines, but have failed to transform the same cells type from 
humans (96). It is now widely accepted that human tumorigenesis is a multistep 
process and requires activation of more than one oncogene (197). 
The goal of this study was three fold. First, to determine whether PTTG can 
induce the transformation of normal human cells; second, to determine if PTTG is 
sufficient to induce transformation, and third, to characterize the changes in secretion 
and expression of the key angiogenic and metastatic factors bFGF, VEGF, IL-8, and 
MMP-2. To address our hypothesis and to investigate the role of PTTG in 
tumorigenesis, I used the human embryonic kidney cell line (HEK293). This cell line 
has been transformed by human adenovirus type 5 to prevent senescence (112) and 
HEK293 cells displays moderate tumorigenic potential (113). 
Our data demonstrate that overexpression of PTTG in HEK293 cells increases 
cell proliferation and induces cellular transformation in vitro as demonstrated by 
colony formation on soft agar and tumor growth in nude mice. By contrast, cells 
transfected with pcDNA 3.1 vector as control did not cause colonies of tumor cells to 
grow in soft agar nor did they promote the development of tumors when implanted in 
nude mice. These results are in agreement with the previous studies (24,27) that 
demonstrated an effect of PTTG to transform NIH3T3 mouse fibroblast cells. Second, 
demonstrated that PTTG alone is sufficient to induce transformation of primary human 
cells without the cooperation of other oncogenes to achieve its tumorigenic function. 
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Often, a single oncogene is not sufficient for the induction of transformation, but 
requires co-operation of other oncogene(s) to induce tumorigenesis in primary human 
cells (96,116,118,119,134,198). However, HEK293 cells are transformed by 
adenovirus type 5, have achieved the limitless growth advantage over their normal 
counterpart. Our data suggest that PTTG is sufficient by itself to initiate the 
transformation of HEK293 cell line, and we have demonstrated that PTTG over-
expression in HEK293 cells accelerates their tumorigenic capacity compared to non-
transfected or vector transfected HEK293 cells. PTTG contains two PXXP motif in the 
proline rich region near C-terminal identified as SH3-binding site (27); these sites are 
critical as mutation of these regions causes the loss of transforming and transactivating 
activity of PTTG. Our data clearly demonstrate that the mutation of these sites 
abrogates the tumorigenic function of PTTG in human cells. The question arises that 
the loss of tumorigenic function of PTTG may be due to loss of expression due to 
mutation, but western blot analysis of a stable clone demonstrated constitutive 
expression of mutated PTTG protein in HEK293 cells. This suggests that the loss of 
tumorigenic function of mutated PTTG clones was not due to loss of expression but 
loss of its ability to induce cellular transformation. Consistent with the results of other 
investigators using rodent cells (27,55), we confirmed the importance of the C-
terminal proline-rich motif in mediating the oncogenic function of PTTG. 
The mechanism of tumorigenesis by which PTTG induces cell transformation 
remains unclear. Apart from the role its cell division, PTTG regulates bFGF 
expression (27). bFGF has previously been implicated in the growth and development 
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of other tumors (75) and the growth of tumors depends mainly on adequate 
vascularization (91). VEGF and IL-8 have also been shown to increase tumor 
vascularization and migration of endothelial cells (108,199,200). Consistent with the 
hypothesis that PTTG may promote tumorigenesis by upregulation of angiogenic 
factors; our data clearly show significant increases in the expression and secretion of 
bFGF, VEGF and IL-8 when PTTG is over-express in HEK293 cells, suggesting, a 
role of PTTG in angiogenesis and tumor promotion. This notion recently raised the 
question that PTTG may form collaborate with other genes to activate the angiogenic 
switch in tumor initiation and progression. McCabe et al (78) investigated several 
angiogenic genes regulated by PTTG in primary thyroid cells. Result from eDNA 
microarray analysis of angiogenic factors showed upregulation of several angiogenic 
promoter genes, including inhibitor of DNA binding-3 (ID3), and down-regulation of 
inhibitors of the angiogenesis gene thrombospondin-l (TSP-l), suggesting that PTTG 
may play an important role in the angiogenesis. 
For a tumor to grow successfully and metastasize, it requires a continuous 
supply of nutrient and oxygen. Without angiogenesis tumors cannot grow larger than 
few mm3 (91). One of the early steps in tumor angiogenesis is degradation of ECM 
catalyzed by MMPs that enable endothelial cells to migrate and proliferate to form 
new vessels (201,202) and to metastasize, by facilitating the movement of tumor cells 
from primary site, to distant organs. Matrix metalloproteinases (MMPs) play a key 
role in this processes by degrading the extracellular matrix and controlling the 
biological activities of growth factors, chemokines and cytokines to favor tumor 
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angiogenesis and metastasis (98). Our data clearly indicate that over-expression of 
PTTG in HEK293 cells increases the expression and secretion of MMP-2. This 
increase of MMP-2 activity is due to an increase in at both mRNA and protein levels 
as demonstrated by MMP-2 promoter activity and zymography analysis. MMP-2 
involved in tumor angiogenesis, mainly through it degradative capacity, and can result 
in tumor cell and endothelial cell migration due to loss of cell-matrix contacts and 
cell-cell contact (145,156,174). Our data indicates that the increase in expression and 
secretion of MMP-2 by PTTG over-expression enhances the invasion and migration of 
both HEK293 and endothelial cells. Increases in MMP-2 secretion also promote the 
tubule formation of HUVEC cells in 3D collagen matrix that is analogous to 
angiogenesis. By using a specific inhibitor that inhibits MMP-2 activity, we showed a 
decrease in MMP-2 activity and loss of its ability for invasion, migration and tubule 
formation of HUVEC, suggesting a specific role of MMP-2 in angiogenesis and cell 
InVasIOn. 
Tumors developed in nude mice show increased expression of MMP-2 mRNA 
and MMP-2 activity, compared to other tissue from same animals. MMP-2 is secreted 
as a latent pro-MMP-2 form, for the activation of MMP-2 it requires a active 
interaction of another class of membrane bound metalloproteinase know as MT -1-
MMP and tissue inhibitor of metalloproteinases-2 (TIMP2) (139). A balance between 
the concentration of MMP-2 and TIMP-2 is needed for the activation of MMP-2 at 
cell surface (203). Our data clearly demonstrate an increase in the expression ofMTl-
MMP and decreased expression of TIMP-2 in the cells over-expressing PTTG 
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compared to cells transfected with vector. These data indicate that PTTO not only 
increases the expression of MMP-2 but also regulates the activity of MMP-2 by 
altering the expression of MT -1-MMP and TIMP-2. 
PTTO over-expreSSIOn has been reported in varIOUS tumors, including 
pituitary (35), thyroid (69,154), colon (33), ovary and breast (25). In thyroid, pituitary, 
oesophageal and colorectal tumors, high PTTO expression correlates with tumor 
invasiveness (27,33,71,154). Furthermore, PTTO has recently been identified as a key 
metastatic "signature gene" with high expression in multiple tumors (36). It remains 
unknown whether PTTO is essential for regulating angiogenesis and metastasis by 
regulating MMP-2 and whether deletion of PTTO will reverse the cancer phenotype 
by decreasing the expression and secretion of MMP-2. Data from our studies show 
that deletion of PTTO from a human colorectal cancer line HCT116 (PTTO -1-) 
decreased expression and secretion of MMP-2. This decrease was associated with 
decreased potential of HCT116 (PTTO -1-) cells to invade through matrigel compared 
to wild type HCT116 (PTTO +1+) cells. Consistent with the results of Kakar and 
Malik (184) and Hassanain et al (unpublished data) and others (70,86,88) using siRNA 
or oligonucleotides method to decrease the expression of PTTO in tumor cells resulted 
in decrease cell proliferation, increase in apoptotic figures, decrease in number of 
colonies formed on soft agar, and inhibition of tumor formation in nude mice. 
In conclusion I demonstrated that PTTO is a potent oncogene, its over-
expression in human cells can induce cellular transformation by increasing the cell 
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proliferation, enhancing colony formation in soft agar in-vitro and, promote tumor 
formation on injection human cells transfected with PTTG cDNA in nude mice. The 
possible mechanism by which PTTG induces angiogenesis, invasion and 
tumorigenesis is by increasing the expression of growth factors such as bFGF, VEGF, 
IL-8 and MMP-2. Depletion of PTTG from the HCTl16 cells appears to abrogate its 
possible role in tumorigenesis by suppression of MMP-2 expression. 
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